Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Jeffrey E Russel Examiner #: 62785 Date: 4-29-2004

Art Unit: 1654 Phone Number 571-272-0969 Serial Number: 10/057,789

Mail Box and Bldg/Room Location: REM 3D11(mailbox), 3D19(office) Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Differential labeling for quantitative analysis of complex protein mixtures

Inventors (please provide full names): P. Haynes, J. Wei, J. Yates, N. Anderson

---

Earliest Priority Filing Date: 1-25-2002

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search SEQ ID NO:1 (ENLYFQG) in STN.

Please exclude Applicants references (US 2002/0087329, US 2003/0082522, and WO 02/59144) from any answer set.

Thank you.

JER

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 09:59:32 ON 29 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 29 Apr 2004  VOL 140 ISS 18
FILE LAST UPDATED: 28 Apr 2004  (20040428/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=>
=>

=> d stat que
L1          137 SEA FILE=REGISTRY ABB=ON  PLU=ON  ENLYFQG/SQSP
L8           55 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 NOT (WO2002059144/PN OR
                US2003082522/PN OR US2002087329/PN)


=>
=>

=> d ibib abs hitrn l8 1-55

L8   ANSWER 1 OF 55  HCAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2004:220360  HCAPLUS
DOCUMENT NUMBER:          140:247082
TITLE:                    Sequences of a human protein kinase C-.eta. and use
                          for treating type 2 diabetes and drug discovery
INVENTOR(S):              Attersand, Anneli; Lake, Staffan
PATENT ASSIGNEE(S):       Biovitrum Ab, Swed.
SOURCE:                   PCT Int. Appl., 58 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
     WO 2004022592      A1   20040318      WO 2003-SE1361   20030903
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
```

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: SE 2002-2608 A 20020904

AB The invention provides sequences of a human protein kinase C-.eta. and its isoforms. The invention also relates to the use of the human Protein Kinase C.eta. (PKC-.eta.) isoform, in methods for identification of pharmaceutically useful agents, in particular agents useful for the treatment of type 2 diabetes.

IT **670342-04-8P**
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; sequences of human protein kinase C-.eta. and use for treating type 2 diabetes and drug discovery)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:219946 HCAPLUS
DOCUMENT NUMBER: 140:249011
TITLE: Membrane scaffold proteins for assembly of target membrane proteins into soluble nanoscale particles
INVENTOR(S): Sligar, Stephen G.; Bayburt, Timothy H.; Schuler, Mary A.; Civjan, Natanya R.; Grinkova, Yelena V.; Denisov, Ilia G.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 70 pp., Cont.-in-part of U.S. Ser. No. 990,087.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004053384	A1	20040318	US 2003-465789	20030618
PRIORITY APPLN. INFO.:			US 2000-252233P P	20001120
			US 2001-990087 A2	20011120

AB Membrane proteins are difficult to express in recombinant form, purify, and characterize, at least in part due to their hydrophobic or partially hydrophobic properties. The membrane scaffold proteins (MSP) of the present invention assemble with target membrane or other hydrophobic or partially hydrophobic proteins or membrane fragments to form sol. nanoscale particles (termed Nanodiscs) which preserve their native structure and function and are improved over liposomes and detergent micelles. In the presence of phospholipid, MSPs form nanoscopic phospholipid bilayer disks, with the MSP stabilizing the particle at the perimeter of the bilayer domain. The particle bilayer structure allows manipulation of incorporated proteins in soln. or on solid supports, including for use with such surface-sensitive techniques as scanning probe microscopy or surface plasmon resonance. The nanoscale particles, which are robust in terms of integrity and maintenance of biol. activity of incorporated proteins, facilitate pharmaceutical and biol. research, structure/function correlation, structure detn., biosepn., and drug discovery.

IT **670338-07-5P**, Scaffolding protein MSP1TEV (synthetic)
670338-09-7P, Scaffolding protein MSP1T2 (synthetic)
670338-11-1P, Scaffolding protein MSP1T3 (synthetic)
RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; membrane scaffold proteins for assembly of target

membrane proteins into sol. nanoscale particles)
IT **670340-87-1**
RL: PRP (Properties)
(unclaimed protein sequence; membrane scaffold proteins for assembly of target membrane proteins into sol. nanoscale particles)
IT **670225-85-1**
RL: PRP (Properties)
(unclaimed sequence; membrane scaffold proteins for assembly of target membrane proteins into sol. nanoscale particles)

L8 ANSWER 3 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:162564 HCAPLUS
DOCUMENT NUMBER: 140:212978
TITLE: Genes for enzymes of shikimate biosynthesis of apicomplexa and use of the enzymes as targets for antiparasitic agents and methods for targeted drug delivery
INVENTOR(S): Mcleod, Rima L.; Mui, Ernest J.; Samuel, Benjamin U.; Mack, Douglas G.; Kirisits, Michael J.; Wender, Paul; Rothbard, Jonathan; Hearn, Brian; Roberts, Craig W.; Rice, David W.; Muench, Stephen P.; Prigge, Sean; Campbell, Samantha A.; Coggins, John R.; Roberts, Fiona; Henriquez, Fiona L.; Milhous, Wilbur K.; Kyle, Dennis E.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016220	A2	20040226	WO 2003-US25571	20030814

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2002-404033P P 20020815
US 2003-438205P P 20030106
US 2003-463432P P 20030416
US 2003-472887P P 20030523

AB Genes for two enzymes of shikimate biosynthesis of the apicomplexan Toxoplasma gondii are identified for use in the development of inhibitors for use as parasiticides. Genes for DAHP synthase and the FabI protein (enoyl acyl carrier protein reductase) are identified. These enzymes may be used as targets for rationally designed drugs, such as derivs. of triclosan as a lead compd. Delivery of inhibitors to microorganisms as conjugates with peptides demonstrates a novel method to treat active infections, and demonstrates a new approach for delivering antimicrobials to encysted, latent parasites. The shikimate pathway is essential for survival of the apicomplexan parasites Plasmodium falciparum, Toxoplasma gondii and Cryptosporidium parvum. The pathway is absent from mammals and so is an appealing therapeutic target. Genes encoding the shikimate pathway enzymes in T. gondii are described. Putative alternate oxidase

(AOX) sequences were identified and sequenced from both type 1 and type 2 strains of C. parvum. The gene encodes a polypeptide of 336 amino acids and has a predicted N-terminal transit sequence similar to that found in proteins targeted to the mitochondria of other species. Alternative oxidase (AOX) is another target for new anti-microbial agents for C. parvum.

IT **663972-01-8**
RL: PRP (Properties)
(unclaimed sequence; genes for enzymes of shikimate biosynthesis of apicomplexa and use of the enzymes as targets for antiparasitic agents and methods for targeted drug delivery)

L8 ANSWER 4 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:120877 HCAPLUS
DOCUMENT NUMBER: 140:177316
TITLE: Histidine tRNA synthetase of Enterococcus faecalis and methods for identifying modulators of this enzyme
INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Domagala, Megan; Nethery, Kathleen; Houston, Simon; Richards, Dawn; Beattie, Bryan; Clarke, Teresa; Kimber, Matthew
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.; et al.
SOURCE: PCT Int. Appl., 287 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013167	A2	20040212	WO 2003-CA1135	20030801

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-400435P P 20020801
US 2003-453405P P 20030310

AB Recombinant histidine tRNA synthetase of Enterococcus faecalis encoded by the hisS gene and the use of this protein or crystal structure information for this protein for identification of HisS-modulating substances are disclosed. The crystal structure of HisS is presented.

IT **503534-87-0**
RL: PRP (Properties)
(unclaimed sequence; histidine tRNA synthetase of Enterococcus faecalis and methods for identifying modulators of this enzyme)

L8 ANSWER 5 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:101185 HCAPLUS
DOCUMENT NUMBER: 140:159633
TITLE: Cloning and physical characterization Enterococcus faecalis peptidyl-tRNA hydrolase and its use as an antimicrobial target
INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Domagala, Megan; Arrowsmith, Cheryl; Mansoury, Kamran; Houston, Simon; Richards, Dawn; Beattie, Bryan

PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 203 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011491	A2	20040205	WO 2003-CA1128	20030731

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-399752P P 20020731

AB The present invention relates to polypeptide targets for pathogenic bacteria. Reliable, high throughput methods are developed to identify, express, and purify peptidyl-tRNA hydrolase from Enterococcus faecalis. The nucleic acid and amino acid sequences, and crystal structure at. coordinates are provided for the peptidyl-tRNA hydrolase. The invention also provides bioinformatic, biochem. and biophys. characteristics of this enzyme, in particular characterization by mass spectrometry, NMR spectrometry, and x-ray crystallog.

IT **503534-87-0**
RL: PRP (Properties)
(unclaimed sequence; cloning and phys. characterization Enterococcus faecalis peptidyl-tRNA hydrolase and its use as an antimicrobial target)

L8 ANSWER 6 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:3469 HCAPLUS
DOCUMENT NUMBER: 140:75949
TITLE: Chimeric antigens comprising viral, tumor and auto-antigen and xenotypic antibody fragment for vaccines against viral infection, cancer and autoimmune disease
INVENTOR(S): George, Rajan; Tyrrell, Lorne; Noujaim, Antoine
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 137 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004001853	A1	20040101	US 2003-365620	20030213

PRIORITY APPLN. INFO.: US 2002-390564P P 20020620
US 2002-423578P P 20021105

AB Disclosed herein are the nucleotide sequences, deduced amino acid sequences as well as methods and compns. necessary to elicit immune responses against infections by hepatitis B virus, hepatitis C virus, herpes simplex virus, HIV, human papillomavirus and cancer in animals and humans. Immune response is enhanced by fusing relevant viral antigens with xenotypic Ig heavy chain region through a peptide linker and

producing the fusion proteins in Baculovirus expression system to incorporate high mannose glycosylation. By virtue of the antibody component, the fusion proteins bind to Fc receptors on the surface of antigen presenting cells, are taken up, processed and derived peptides are presented on MHC Class I, which elicit a CTL (Th1) response. In a similar fashion, due to cross priming and presentation on MHC Class II, will elicit a humoral (Th2) response. In addn., disclosed are the methods of cloning, expression and prodn. of the fusion proteins.

IT **641643-88-1P 641643-90-5P 641643-92-7P**
641643-94-9P 641643-96-1P 641643-98-3P
641644-00-0P 641644-02-2P 641644-04-4P
641644-06-6P 641644-08-8P 641644-10-2P
641644-12-4P 641644-14-6P 641644-16-8P
641644-18-0P 641644-20-4P, Protein E1 (hepatitis C virus) **641644-22-6P 641644-24-8P**, Protein E2 (hepatitis C virus) **641644-26-0P 641644-28-2P**
641644-30-6P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; chimeric antigens comprising viral, tumor and auto- antigen and xenotypic antibody fragment for vaccines against viral infection, cancer and autoimmune disease)

IT **641653-51-2 641653-55-6 641653-57-8**
641653-58-9 641653-61-4 641653-87-4
641653-90-9 641653-92-1 641653-94-3
RL: PRP (Properties)
(unclaimed protein sequence; chimeric antigens comprising viral, tumor and auto- antigen and xenotypic antibody fragment for vaccines against viral infection, cancer and autoimmune disease)

L8 ANSWER 7 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:972222 HCAPLUS
DOCUMENT NUMBER: 140:37977
TITLE: Cloning and physical characterization of microbial polypeptides involved in protein synthesis and modification and their use as antimicrobial targets
INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Vallee, Francois; Awrey, Donald; Beattie, Bryan; Richards, Dawn; Domagala, Megan; Mansoury, Kamran; Virag, Cristina; Buzadzija, Kristina; McDonald, Merry-Lynn; Houston, Simon; Arrowsmith, Cheryl; Ouyang, Hui
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 606 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003102190	A2	20031211	WO 2003-CA786	20030602

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,

GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2002-384634P	P	20020531
US 2002-385157P	P	20020531
US 2002-385542P	P	20020604
US 2002-385611P	P	20020604
US 2002-385747P	P	20020604
US 2002-385750P	P	20020604
US 2002-385752P	P	20020604
US 2002-385773P	P	20020604
US 2002-385780P	P	20020604
US 2002-385785P	P	20020604
US 2002-385797P	P	20020604
US 2002-385962P	P	20020605
US 2002-386022P	P	20020605
US 2002-386024P	P	20020605
US 2002-386087P	P	20020605
US 2002-386141P	P	20020605
US 2002-386350P	P	20020605
US 2002-386586P	P	20020605
US 2002-386368P	P	20020606
US 2002-386369P	P	20020606
US 2002-386436P	P	20020606
US 2002-386441P	P	20020606
US 2002-386528P	P	20020606
US 2002-386573P	P	20020606
US 2002-386834P	P	20020606
US 2002-399839P	P	20020731
US 2002-399861P	P	20020731
US 2002-399969P	P	20020731
US 2002-399970P	P	20020731
US 2002-399983P	P	20020731
US 2002-399984P	P	20020731
US 2002-399985P	P	20020731
US 2002-400268P	P	20020801
US 2002-400363P	P	20020801
US 2002-400436P	P	20020801
US 2002-400442P	P	20020801

AB The present invention relates to polypeptide targets for pathogenic bacteria. Reliable, high throughput methods are developed to identify, express, and purify a no. of antimicrobial targets from Staphylococcus aureus, Escherichia coli, Streptococcus pneumoniae, Enterococcus faecalis, Helicobacter pylori, and Pseudomonas aeruginosa. The invention also provides bioinformatic, biochem. and biophys. characteristics of those polypeptides, in particular characterization by mass spectrometry, NMR spectrometry, and x-ray crystallog.

IT **503534-87-0**
RL: PRP (Properties)
(unclaimed sequence; cloning and phys. characterization of microbial polypeptides involved in protein synthesis and modification and their use as antimicrobial targets)

L8 ANSWER 8 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:969413 HCAPLUS
DOCUMENT NUMBER: 140:26931
TITLE: Protein and cDNA sequences of major allergen of pollen of Artemisia vulgaris (mugwort)
INVENTOR(S): Ferreira, Fatima; Hubinger, Gudrun; Ebner, Christof; Richter, Klaus
PATENT ASSIGNEE(S): Biomay Produktions- und Handels- Aktiengesellschaft, Austria
SOURCE: Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1369483	A1	20031210	EP 2002-12302	20020604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2003102189	A1	20031211	WO 2003-EP5780	20030603
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2002-12302 A 20020604

AB The present invention relates to protein and cDNA sequences of 40.9 kDa allergen from mugwort pollen. The invention further pertains to antibodies directed against the allergen and to the use of the materials described for the manuf. of a medicament for the treatment or prevention of an allergic disorder. The invention also relates to expression of Artemisia vulgaris allergen in Escherichia coli and purifn. of recombinant allergen by immunoaffinity chromatog.

IT **631936-75-9**
RL: PRP (Properties)
(unclaimed sequence; protein and cDNA sequences of major allergen of pollen of Artemisia vulgaris (mugwort))

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:931464 HCAPLUS
DOCUMENT NUMBER: 140:2343
TITLE: Cloning and physical characterization of farnesyl diphosphate synthase from Pseudomonas aeruginosa and its use as a antimicrobial target
INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Mansoury, Kamran; Houston, Simon; Vallee, Francois; Kimber, Matthew
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 240 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097789	A2	20031127	WO 2003-CA714	20030521
WO 2003097789	A3	20040205		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ,				

MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-382443P P 20020521

AB The present invention relates to polypeptide targets for pathogenic bacteria. Reliable, high throughput methods are developed to identify, express, and purify the farnesyl diphosphate synthase protein Pseudomonas aeruginosa. The invention also provides bioinformatic, biochem. and biophys. characteristics of those polypeptides, in particular characterization by mass spectrometry, NMR spectrometry, and x-ray crystallog.

IT **503534-87-0**
RL: PRP (Properties)
(unclaimed sequence; cloning and phys. characterization of farnesyl diphosphate synthase from Pseudomonas aeruginosa and its use as a antimicrobial target)

L8 ANSWER 10 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:913293 HCAPLUS
DOCUMENT NUMBER: 139:377249
TITLE: Method for generating gene mutation by activation induced deaminase (AID)
INVENTOR(S): Petesersen-Mahrt, Svend K.; Harris, Reuben S.; Neuberger, Michael Samuel; Beale, Rupert Christopher Lansdowne
PATENT ASSIGNEE(S): Medical Research Council, UK
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003095636	A2	20031120	WO 2003-GB2002	20030509
WO 2003095636	A3	20040212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2002-10755 A 20020510
GB 2002-13751 A 20020614
GB 2002-17519 A 20020729

AB The present invention identifies that the expression of activation induced deaminase (AID) or its homologues in cells confers a mutator phenotype and thus provides a method for generating diversity in a gene or gene product as well as cell lines capable of generating diversity in defined gene products. The invention also provides methods of modulating a mutator phenotype by modulating AID expression or activity.

IT **623534-89-4**
RL: PRP (Properties)
(unclaimed sequence; method for generating gene mutation by activation induced deaminase (AID))

L8 ANSWER 11 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:913281 HCAPLUS
DOCUMENT NUMBER: 139:393169
TITLE: Protein complex purification
INVENTOR(S): Boniface, John J.; Kery, Vladimir; Peltier, John M.; Weir, Lawrence; Robbins, Paul B.; Rodriguez, Manuel M.
PATENT ASSIGNEE(S): Myriad Proteomics, Inc., USA
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003095619	A2	20031120	WO 2003-US14511	20030509

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-379317P P 20020509
AB The present invention provides a method for isolating protein complexes from a cell, a cell or tissue lysate or an whole organism by employing a combined set of affinity tags of high affinity, specificity and ease of elution. The method involves using a known protein modified to contain more than one affinity tag sepd. by one or more specific protease cleavage sites, as bait, to isolate any interacting proteins or fragments thereof. The proteins or fragments thereof contained in the isolated complex can then be identified and the interacting partners can be used as new targets for diagnostic tools or the basis for the development of new compds. for therapeutic drug intervention.
IT **158760-86-2**
RL: NUU (Other use, unclassified); USES (Uses)
(protein complex purifn.)
IT **625485-94-1 625485-96-3 625485-98-5 625486-00-2**
RL: PRP (Properties)
(unclaimed protein sequence; protein complex purifn.)

L8 ANSWER 12 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:855956 HCAPLUS
DOCUMENT NUMBER: 139:347484
TITLE: Cloning, sequence, crystal structure and physical characterization of (3R)-hydroxymyristoyl-(acyl-carrier-protein) dehydratase from Pseudomonas aeruginosa and its use as antimicrobial target
INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Domagala, Megan; McDonald, Merry-Lynn; Houston, Simon; Vallee, Francois; Kimber, Matthew; Awrey, Donald; Beattie, Bryan
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 304 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003089463	A1	20031030	WO 2003-CA560	20030417

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-373321P P 20020417

AB The present invention relates to novel drug targets for pathogenic bacteria. Reliable, high throughput methods are developed to identify, express, and purify (3R)-hydroxymyristoyl-(acyl-carrier-protein) dehydratase from P. aeruginosa. The invention provides the nucleic acid sequence and the encoded amino acid sequence of the enzyme. The invention also provides crystal structure and other biochem. and biophys. characteristics of the P. aeruginosa (3R)-hydroxymyristoyl-(acyl-carrier-protein) dehydratase.

IT **503534-87-0**
RL: PRP (Properties)
(unclaimed sequence; cloning, sequence, crystal structure and phys. characterization of (3R)-hydroxymyristoyl-(acyl-carrier-protein) dehydratase from Pseudomonas aeruginosa and its use as antimicrobial target)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:837271 HCAPLUS
DOCUMENT NUMBER: 139:334822
TITLE: Cloning, sequence and physical characterization of enolase from pathogenic bacteria and their use as antimicrobial targets
INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Domagala, Megan; Nethery, Kathleen; Buzadzija, Kristina; Houston, Simon; Ng, Ivy; Vallee, Francois; Awrey, Donald; Beattie, Bryan
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 439 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087352	A2	20031023	WO 2003-CA506	20030409
WO 2003087352	A3	20040205		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,

TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-371132P P 20020409
US 2002-371365P P 20020410
US 2002-371911P P 20020411

AB The present invention relates to novel drug targets for pathogenic bacteria. The nucleic acid and amino acid sequences are provided for enolases from Staphylococcus aureus, Helicobacter pylori, and Streptococcus pneumoniae. The invention also provides bioinformatic, biochem. and biophys. characteristics of those polypeptides, in particular characterization by mass spectrometry, NMR spectrometry, and x-ray crystallog.

IT **503534-87-0**
RL: PRP (Properties)
(unclaimed sequence; cloning, sequence and phys. characterization of enolase from pathogenic bacteria and their use as antimicrobial targets)

L8 ANSWER 14 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:837132 HCAPLUS
DOCUMENT NUMBER: 139:319015
TITLE: Sequences of the modified oncomodulin-containing luminescent protein terbofluor (TBF) and use as markers
INVENTOR(S): Hogue, Christopher; Sroka, Susanna
PATENT ASSIGNEE(S): Mount Sinai Hospital, Can.
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087152	A1	20031023	WO 2003-CA546	20030411

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-372382P P 20020411

AB The invention provides sequences of the modified oncomodulin-contg. luminescent protein TBF. In particular, a luminescent protein is provided comprising oncomodulin in which a salt bridge has been introduced to provide greater stability. The protein may be used as a luminescent marker in, for example, luminescent items, immunoassays, and fluorescent energy transfer assays.

IT **612560-03-9P**
RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); PREP (Preparation)
(amino acid sequence; sequences of modified oncomodulin-contg.

luminescent protein terbofluor (TBF) and use as markers)
IT **158760-86-2**
RL: PRP (Properties)
(unclaimed nucleotide sequence; sequences of the modified oncomodulin-contg. luminescent protein terbofluor (TBF) and use as markers)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:737279 HCAPLUS
DOCUMENT NUMBER: 139:257286
TITLE: Cloning and sequences of bacterial nicotinamide ribonucleoside kinase (NRKse) and use of NRKse for drug screening and production of .beta.-NMN
INVENTOR(S): Kurnasov, Oleg; Polanuyer, Boris; Kogan, Yakov; Osterman, Andrei
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 53 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003175925	A1	20030918	US 2001-793705	20010227

PRIORITY APPLN. INFO.: US 2001-793705 20010227
AB The present invention relates to novel nicotinamide ribonucleoside kinase (NmR kinase, NRKse) nucleic acids, polypeptides, and uses thereof. The nucleotide sequences and the encoded amino acid sequences of bacterial NadR proteins cong. NRKse domain are disclosed. Cloning and recombinant expression of the NRKse of the invention is described. Fusion proteins and anti-NRKse antibodies are provided. The NRKse of the invention can be used in drug screening assay and for prodn. of .beta.-NMN or analogs.
IT **602373-24-0 602373-26-2 602373-28-4 602373-30-8**
RL: PRP (Properties)
(unclaimed sequence; cloning and sequences of bacterial nicotinamide ribonucleoside kinase (NRKse) and use of NRKse for drug screening and prodn. of .beta.-NMN)

L8 ANSWER 16 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:696462 HCAPLUS
DOCUMENT NUMBER: 139:207733
TITLE: Construction of recombinant single-chain toxins for use in vaccines and toxin assays
INVENTOR(S): Shone, Clifford Charles; Quinn, Conrad Padraig; Foster, Keith Alan; Chaddock, John; Marks, Philip; Sutton, J. Mark; Stancombe, Patrick; Wayne, Jonathan
PATENT ASSIGNEE(S): Microbiological Research Authority, UK; Speywood Laboratory Limited
SOURCE: U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U.S. Ser. No. 255,829.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2003166238 A1 20030904 US 2002-241596 20020912
WO 9807864 A1 19980226 WO 1997-GB2273 19970822
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
ZA 9707541 A 19980416 ZA 1997-7541 19970822
US 2002044950 A1 20020418 US 1999-255829 19990223
US 6461617 B1 20021008
WO 2004024909 A2 20040325 WO 2003-GB3824 20030912
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: GB 1996-17671 A 19960823
GB 1996-25996 A 19961213
US 1996-782893 B2 19961227
WO 1997-GB2273 W 19970822
US 1999-242689 B1 19990223
US 1999-255829 A2 19990223
US 2002-241596 A 20020912

AB A single-chain polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane assocd. proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the soly. of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity assocd. with the natural mol. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.

IT **588806-56-8P**
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; construction of recombinant single-chain toxins for use in vaccines and toxin assays)

L8 ANSWER 17 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:643181 HCAPLUS
DOCUMENT NUMBER: 139:144993
TITLE: Sequences of human interferon .alpha. variants with super-strong antiviral activity
INVENTOR(S): Fan, Kai; Ma, Suyong; Zhang, Yi; Wang, Jian; Liu, Fan; Nie, Liya
PATENT ASSIGNEE(S): Chongqing Fujin Biomedicine Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 13 pp.
CODEN: CNXXEV

DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1365983	A	20020828	CN 2001-102915	20010119

PRIORITY APPLN. INFO.: CN 2001-102915 20010119

AB The invention provides the amino acid sequence (171 aa) of a human interferon .alpha. deriv. (IFN-SA) with super-strong antiviral activity. The invention relates to the prepn. of IFN-SA by constructing the recombinant expression vector, transforming into receptor (such as E. coli, yeast, or mammalian cell), fermenting, and purifying. The invention also relates to the application of IFN-SA in preventing and treating viral infection.

IT **158760-86-2 572898-80-7**
RL: PRP (Properties)
(unclaimed sequence; sequences of human interferon .alpha. variants with super-strong antiviral activity)

L8 ANSWER 18 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:532785 HCAPLUS
DOCUMENT NUMBER: 139:97274
TITLE: Identification, characterization and drug screening use of AMP kinase .beta.-subunit oligosaccharide-binding domain
INVENTOR(S): Stapleton, David; Kemp, Bruce E.
PATENT ASSIGNEE(S): St. Vincent's Institute of Medical Research, Australia
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003056032	A1	20030710	WO 2002-AU1769	20021223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: AU 2001-9728 A 20011221

AB The present invention relates to the identification of an oligosaccharide binding domain in the .beta.-subunit of AMP kinase (AMPK). Consensus sequence for the oligosaccharide binding domain of the .beta. subunit of members of the AMPK protein family and consensus sequence for the oligosaccharide binding domain of mammalian AMPK are provided. Exemplary cloning, expression, purifn., crystal structure and other properties of rat AMPK .beta.1-subunit oligosaccharide binding domain are described. Methods are provided for screening for compds. that modulate oligosaccharide binding to the .beta.-subunit of AMPK. Methods of using such compd. in the treatment of conditions assocd. with uncoupled AMPK activity are also provided.

IT **558539-30-3**

RL: PRP (Properties)
(unclaimed protein sequence; identification, characterization and drug screening use of AMP kinase .beta.-subunit oligosaccharide-binding domain)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 19 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:532682 HCAPLUS
DOCUMENT NUMBER: 139:97272
TITLE: Cloning, characterization, sequence and crystal structure of peptidyl-tRNA hydrolase from Pseudomonas aeruginosa and use of the structural data for drug screening and drug design
INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Domagala, Megan; Pinder, Benjamin; Alam, Muhammad Zahoor; Vedadi, Masoud; Wrezel, Olga; Houston, Simon; Kimber, Matthew; Vallee, Francois; Awrey, Donald; Beattie, Bryan
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.; et al.
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055904	A2	20030710	WO 2002-CA1977	20021220
WO 2003055904	A3	20030821		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-344112P P 20011221
US 2002-370755P P 20020408

AB The present invention relates to novel drug targets for pathogenic bacteria. The authors have identified, expressed and purified a novel antimicrobial target from Pseudomonas aeruginosa. The nucleotide sequence and the encoded amino acid of peptidyl-tRNA hydrolase from P. aeruginosa are provided. The invention also provides bioinformatic, biochem. and biophys. characteristics of the polypeptides of the invention. The X-ray crystal structure and three-dimensional structure of the P. aeruginosa hydrolase are disclosed. Methods of drug screening and drug design based on structural information on the polypeptides of the invention are provided.
IT **503534-87-0**
RL: PRP (Properties)
(unclaimed sequence; cloning, characterization, sequence and crystal structure of peptidyl-tRNA hydrolase from Pseudomonas aeruginosa and use of the structural data for drug screening and drug design)

L8 ANSWER 20 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:491262 HCAPLUS
DOCUMENT NUMBER: 139:65421
TITLE: Biophysical and bioinformatic characterization of

NH3-dependent NAD synthetase from Streptococcus pneumoniae and its use as a antimicrobial drug target
INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Alam, Muhammad Zahoor; Houston, Simon; Pinder, Benjamin; Ng, Ivy; Lam, Robert; Kimber, Matthew
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 233 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051916	A2	20030626	WO 2002-CA1934	20021218
WO 2003051916	A3	20030912		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-342171P P 20011218
AB The present invention relates a polypeptide drug target from pathogenic bacteria, specifically the NH3-dependent NAD synthetase (gene nadE) from Streptococcus pneumoniae. The invention also provides biochem. and biophys. characteristics of this polypeptide. Reliable, high-throughput methods are developed to identified, express, and purify this enzyme from Streptococcus pneumoniae. The invention also provides purified, sol. forms of NH3-dependent NAD synthetase polypeptides suitable for structural and functional characterization using a variety of techniques, including, for example, affinity chromatog., mass spectrometry, NMR, and x-ray crystallog. The invention further provides modified versions of the polypeptides to facilitate characterization, including polypeptides labeled with isotopic or heavy atoms and fusion proteins. One or more crystd. forms of the polypeptides may also be provided.
IT **503534-87-0**
RL: PRP (Properties)
(unclaimed sequence; biophys. and bioinformatic characterization of NH3-dependent NAD synthetase from Streptococcus pneumoniae and its use as a antimicrobial drug target)

L8 ANSWER 21 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:434591 HCAPLUS
DOCUMENT NUMBER: 139:18838
TITLE: Bacterial polypeptides involved in general metabolism and their characterization as antimicrobial targets
INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Alam, Muhammad Zahoor; Awrey, Donald; Beattie, Bryan; Canadien, Veronica; Domagala, Megan; Houston, Simon; Li, Qin; Mansoury, Kamran; Necakov, Sasha; Nethery, Kathleen; Ouyang, Hui; Pinder, Benjamin; Sheldrick, Bay; Vallee, Francois; Wrezel, Olga
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.; et al.
SOURCE: PCT Int. Appl., 272 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045986	A2	20030605	WO 2002-CA1785	20021126
WO 2003045986	A3	20031211		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-333340P	P	20011126
US 2001-333342P	P	20011126
US 2001-333414P	P	20011126
US 2001-333419P	P	20011126
US 2001-333423P	P	20011126
US 2001-341951P	P	20011219
US 2001-342557P	P	20011220
US 2001-342558P	P	20011220
US 2001-343613P	P	20011228
US 2001-344272P	P	20011228

AB The present invention relates to ten polypeptide targets for pathogenic bacteria. The invention also provides biochem. and biophys. characteristics of those polypeptides. Reliable, high throughput methods are developed to identified, express, and purify a no. of antimicrobial targets from Escherichia coli, Staphylococcus aureus, Helicobacter pylori, Staphylococcus pneumoniae, and Pseudomonas aeruginosa. The invention provides the nucleic acid and amino acid sequences of glucose-inhibited division protein from E. coli, fructose bisphosphate aldolase from S. aureus, replicative DNA helicase primosome component from H. pylori, protein factor essential for expression of methicillin resistance from S. aureus, glucosamine-fructose-6-phosphate aminotransferase from S. aureus, N utilization substance protein B from S. pneumoniae, N utilization substance protein A from P. aeruginosa, putative GTP-binding protein from G. aeruginosa, 2-dehydro-3-deoxyphosphooctonate aldolase from P. aeruginosa, and putative GTP-binding protein in thiophene and furan oxidn. from S. aureus. The invention also provides purified, sol. forms of polypeptides suitable for structural and functional characterization using a variety of techniques, including, for example, affinity chromatog., mass spectrometry, NMR, and x-ray crystallog. The invention further provides modified versions of the polypeptides to facilitate characterization, including polypeptides labeled with isotopic or heavy atoms and fusion proteins. One or more crystd. forms of the polypeptides may also be provided.

IT **503534-87-0**
RL: PRP (Properties)
(unclaimed sequence; bacterial polypeptides involved in general metab. and their characterization as antimicrobial targets)

L8 ANSWER 22 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:434590 HCAPLUS
DOCUMENT NUMBER: 139:18837
TITLE: Bacterial polypeptides involved in carbohydrate and coenzyme metabolism and their characterization as antimicrobial targets

INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Ng, Ivy; Alam, Muhammad Zahoor; Awrey, Donald; Beattie, Bryan; Domagala, Megan; Mansoury, Kamran; Pinder, Benjamin
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 191 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045985	A2	20030605	WO 2002-CA1784	20021126
WO 2003045985	A3	20040311		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2001-333349P P 20011126
US 2001-333420P P 20011126
US 2001-341950P P 20011219
US 2001-343643P P 20011228

AB The present invention relates to ten polypeptide targets for pathogenic bacteria. The invention also provides biochem. and biophys. characteristics of those polypeptides. Reliable, high throughput methods are developed to identified, express, and purify a no. of antimicrobial targets from Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa. The invention provides the nucleic acid and amino acid sequences of phosphoglycerate kinase from S. aureus, flavoprotein affectin synthesis of DNA and pantothenate from E. coli, riboflavin kinase/FAD synthase from S. aureus, and phosphopantetheine adenylyltransferase from P. aeruginosa. The invention also provides purified, sol. forms of polypeptides suitable for structural and functional characterization using a variety of techniques, including, for example, affinity chromatog., mass spectrometry, NMR, and x-ray crystallog. The invention further provides modified versions of the polypeptides to facilitate characterization, including polypeptides labeled with isotopic or heavy atoms and fusion proteins. One or more crystd. forms of the polypeptides may also be provided.

IT **503534-87-0**
RL: PRP (Properties)
(unclaimed sequence; bacterial polypeptides involved in carbohydrate and coenzyme metab. and their characterization as antimicrobial targets)

L8 ANSWER 23 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:417856 HCAPLUS
DOCUMENT NUMBER: 139:18834
TITLE: Human exosome protein subunits for regulation of gene expression through modulation of mRNA turnover and therapeutic uses thereof
INVENTOR(S): Chen, Ching-Yi; Karin, Michael
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 127 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003044166	A2	20030530	WO 2002-US36665	20021114
WO 2003044166	A3	20031231		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-334712P P 20011115

AB The present invention provides means to modulate gene expression by destabilizing or stabilizing mRNA species. The invention provides compns. and methods for altering the level of RNA, and for screening test agents that alter RNA levels. Specifically, the invention claims peptide sequences for human exosome assocd. protein p1 and use of mammalian exosomes, AU-rich RNA elements, and AU-rich element-binding proteins. Recombinant expression of a human Rrp4p polypeptide is claimed and also a transgenic cell line, designated JurkatRrp4-TAP. Further, compns. and methods of the invention are claimed for regulation of cytokine, hormone, or oncogene gene expression and for treatment of immune diseases, inflammatory diseases, hormone deficiencies, or cancer. C-fos RNA is degraded by the human exosome in a cell-free ext. and the degrdn. requires an AU-rich element (ARE) in the 3' region of c-fos RNA. The examples also show purifn. of the human exosome, mol. identification of its component proteins, interaction of the exosome with ARE-binding proteins (AUBP), and role of recombinant AUBPs in exosome-mediated RNA decay.

IT **537055-51-9**
RL: PRP (Properties)
(unclaimed protein sequence; human exosome protein subunits for regulation of gene expression through modulation of mRNA turnover and therapeutic uses thereof)

L8 ANSWER 24 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:261864 HCAPLUS
DOCUMENT NUMBER: 138:282444
TITLE: Cloning, purification and characterization of polypeptides from pathogenic bacteria involved in membrane biosynthesis, and drug screening and drug design applications
INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Alam, Muhammad Zahoor; Awrey, Donald; Beattie, Bryan; Canadien, Veronica; Domagala, Megan; Houston, Simon; Kanagarajah, Dhushy; Li, Qin; Mansoury, Kamran; McDonald, Merry-Lynn; Necakov, Sasha; Ng, Ivy; Pinder, Benjamin; Sheldrick, Bay; Vallee, Francois; Viola, Cristina; Wrezel, Olga
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 312 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003027139	A2	20030403	WO 2002-CA1443	20020924
WO 2003027139	A3	20040219		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-324449P	P	20010924
US 2001-324504P	P	20010924
US 2001-326269P	P	20011001
US 2001-326887P	P	20011003
US 2001-339560P	P	20011024
US 2001-337471P	P	20011025
US 2001-340000P	P	20011026
US 2001-340002P	P	20011026
US 2001-340027P	P	20011026
US 2001-341767P	P	20011218
US 2001-344307P	P	20011221
US 2001-343946P	P	20011227

AB The present invention relates to polypeptide targets for pathogenic bacteria. A no. of antimicrobial target enzymes and proteins have been identified, expressed, and purified from Staphylococcus aureus, Helicobacter pylori, Streptococcus pneumoniae, and Pseudomonas aeruginosa. Cloning, the nucleotide sequences and the encoded amino acid sequences of genes ftsZ, fabZ, acpS, murD, murC, fabH, tagD, obg, and fabG from S. aureus, H. pylori, S. pneumoniae, and P. aeruginosa are disclosed. The invention also provides biochem. and biophys. characteristics of those polypeptides. The polypeptides are characterized by using mass spectrometry, NMR, x-ray crystallog., and bioinformatics anal. The polypeptides of the invention can be used for drug screening, drug design, in diagnostic assays and in pharmacol. applications.

IT **504406-78-4**
RL: PRP (Properties)
(unclaimed sequence; cloning, purifn. and characterization of polypeptides from pathogenic bacteria involved in membrane biosynthesis, and drug screening and drug design applications)

L8 ANSWER 25 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:244781 HCAPLUS
DOCUMENT NUMBER: 138:283688
TITLE: Nucleic acids, vectors, fusion proteins and method for detection and identification of protein ligands
INVENTOR(S): Bonneu, Marc; Crouzet, Marc
PATENT ASSIGNEE(S): Universite Victor Segalen Bordeaux 2, Fr.
SOURCE: Fr. Demande, 74 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

FR 2830020	A1	20030328	FR 2001-12337	20010925
FR 2830020	B1	20031219		

PRIORITY APPLN. INFO.: FR 2001-12337 20010925

AB A nucleic acid encoding a marker protein (such as GFP) fused to an affinity purifn. peptide, a chimeric gene consisting of the nucleic acid fused to a bait protein, and vectors contg. such chimeric genes are disclosed. Cells transformed with such vectors may be used for localization of the ligand(s) of the bait protein. Alternatively, the cell may be lysed and the complex composed of the bait protein-GFP-affinity peptide and ligand may be isolated by affinity chromatog. and may be characterized by gel exclusion chromatog. Thus, a fusion protein comprising Ade4p, GFP, calmodulin-binding peptide, and hexahistidine was expressed in yeast. A 320-kDa complex was identified by gel filtration and purified on calmodulin and nickel ion affinity columns. The 320-kDa complex was found to be a tetramer of the Adep-GFP fusion protein.

IT **503640-32-2**, Fusion protein (synthetic)
RL: ARU (Analytical role, unclassified); PRP (Properties); ANST (Analytical study)
(amino acid sequence; nucleic acids, vectors, fusion proteins and method for detection and identification of protein ligands)

IT **158760-86-2**
RL: PRP (Properties)
(unclaimed sequence; nucleic acids, vectors, fusion proteins and method for detection and identification of protein ligands)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 26 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:242372 HCAPLUS
DOCUMENT NUMBER: 138:283070
TITLE: Purification of enzymes involved in protein synthesis from pathogenic bacteria for characterization in development of targets for antibiotics
INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Alam, Muhammad Zahoor; Awrey, Donald; Beattie, Bryan; Canadien, Veronica; Domagala, Megan; Houston, Simon; Kanagarajah, Dhushy; Necakov, Sasha; Nethery, Kathleen; Ng, Ivy; Mansoury, Kamran; McDonald, Merry-Lynn; Pinder, Benjamin; Sheldrick, Bay; Viola, Cristina
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 254 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025008	A2	20030327	WO 2002-CA1429	20020920

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,

NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-324176P P 20010921
US 2001-324439P P 20010924
US 2001-324690P P 20010925
US 2001-324713P P 20010925
US 2001-326336P P 20011001
US 2001-341466P P 20011217
US 2001-341764P P 20011218
US 2001-341918P P 20011219

AB Methods of purifying and characterizing enzymes that may play a role in protein synthesis in pathogenic bacteria are described. The proteins may be useful as targets for antibiotics and methods for identifying regions of the proteins that may be targeted by drugs are described. The invention also provides biochem. and biophys. characteristics of those polypeptides.

IT **503534-87-0**
RL: PRP (Properties)
(unclaimed sequence; purifn. of enzymes involved in protein synthesis from pathogenic bacteria for characterization in development of targets for antibiotics)

L8 ANSWER 27 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:242371 HCAPLUS
DOCUMENT NUMBER: 138:283069
TITLE: Purification of proteins of microbial cell wall biosynthesis from pathogenic bacteria for characterization in development of targets for antibiotics
INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Alam, Muhammad Zahoor; Awrey, Donald; Beattie, Bryan; Domagala, Megan; Houston, Simon; Kanagarajah, Dhushy; Nethery, Kathleen; Ng, Ivy; Mansoury, Kamran; McDonald, Merry-Lynn; Pinder, Benjamin; Viola, Cristina; Wrezel, Olga
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 325 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025007	A2	20030327	WO 2002-CA1428	20020920
WO 2003025007	A3	20040304		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-323992P P 20010921
US 2001-324152P P 20010921
US 2001-324692P P 20010925
US 2001-339924P P 20011026
US 2001-350973P P 20011029
US 2001-340924P P 20011030

US 2001-333666P P 20011127
US 2001-341732P P 20011218
US 2001-341776P P 20011218
US 2001-341949P P 20011219

AB Methods of purifying and characterizing enzymes that may play a role in microbial cell wall biosynthesis in pathogenic bacteria are described. The proteins may be useful as targets for antibiotics and methods for identifying regions of the proteins that may be targeted by drugs are described. The invention also provides biochem. and biophys. characteristics of those polypeptides.

IT **503534-87-0**
RL: PRP (Properties)
(unclaimed sequence; purifn. of proteins of microbial cell wall biosynthesis from pathogenic bacteria for characterization in development of targets for antibiotics)

L8 ANSWER 28 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:242370 HCAPLUS
DOCUMENT NUMBER: 138:267686
TITLE: Purification of enzymes involved in coenzyme metabolism from pathogenic bacteria for characterization in development of targets for antibiotics
INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Alam, Muhammad Zahoor; Awrey, Donald; Beattie, Bryan; Canadien, Veronica; Domagala, Megan; Houston, Simon; Kanagarajah, Dhushy; Li, Qin; Necakov, Sasha; Nethery, Kathleen; Pinder, Benjamin; Sheldrick, Bay; Vallee, Francois; Viola, Cristina
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 256 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025006	A2	20030327	WO 2002-CA1427	20020920
WO 2003025006	A3	20040219		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2001-324115P P 20010921
US 2001-325337P P 20010927
US 2001-326321P P 20011001
US 2001-326378P P 20011001
US 2001-326820P P 20011003
US 2001-335702P P 20011025
US 2001-340536P P 20011026
US 2001-350907P P 20011029

AB Methods of purifying and characterizing enzymes that may play a role in cofactor metab. in pathogenic bacteria are described. The proteins may be useful as targets for antibiotics and methods for identifying regions of

the proteins that may be targeted by drugs are described. The invention also provides biochem. and biophys. characteristics of those polypeptides.

IT **503534-87-0**
RL: PRP (Properties)
(unclaimed sequence; purifn. of enzymes involved in coenzyme metab. from pathogenic bacteria for characterization in development of targets for antibiotics)

L8 ANSWER 29 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:242369 HCAPLUS
DOCUMENT NUMBER: 138:283309
TITLE: Cloning, purification and characterization of enzymes from pathogenic bacteria involved in protein processing and drug screening and drug design applications
INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Alam, Muhammad Zahoor; Awrey, Donald; Beattie, Bryan; Canadien, Veronica; Domagala, Megan; Kanagarajah, Dhushy; Li, Qin; Mansoury, Kamran; Necakov, Sasha; Nethery, Kathleen; Ng, Ivy; Pinder, Benjamin; Sheldrick, Bay; Vallee, Francois; Viola, Cristina; Wrezel, Olga; et al.
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 273 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025005	A2	20030327	WO 2002-CA1426	20020920
WO 2003025005	A3	20040311		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-324135P	P	20010921
US 2001-324139P	P	20010921
US 2001-325333P	P	20010927
US 2001-325836P	P	20010928
US 2001-338235P	P	20011025
US 2001-343758P	P	20011025
US 2001-340531P	P	20011026
US 2001-340945P	P	20011030
US 2001-333281P	P	20011106
US 2002-399926P	P	20020731

AB The present invention relates to polypeptide targets for pathogenic bacteria. A no. of antimicrobial target enzymes have been identified, expressed, and purified from Staphylococcus aureus, Helicobacter pylori, Streptococcus pneumoniae, and Escherichia coli. Cloning, the nucleotide sequences and the encoded amino acid sequences of genes clpL, cysM, pepP, kdsA, secA, trmD, ilvE, aroB, and glyA from S. aureus, H. pylori, S. pneumoniae, and E. coli are disclosed. The invention also provides biochem. and biophys. characteristics of those polypeptides. The

polypeptides are characterized by using mass spectrometry, NMR, x-ray crystallog., and bioinformatics anal. The polypeptides of the invention can be used for drug screening, drug design, in diagnostic assays and in pharmacol. applications.

IT **503534-87-0**
RL: PRP (Properties)
(unclaimed sequence; cloning, purifn. and characterization of enzymes from pathogenic bacteria involved in protein processing and drug screening and drug design applications)

L8 ANSWER 30 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:210107 HCAPLUS
DOCUMENT NUMBER: 138:216504
TITLE: Fusion protein construct for recombinant production of human growth hormone in Bacillus bacteria
INVENTOR(S): Sato, Seiji; Kondo, Masaaki; Kudo, Toshiyuki; Endo, Kosuke; Watanabe, Shigeaki; Waki, Yoshihiro; Yamanaka, Masaya
PATENT ASSIGNEE(S): Ito Ham Foods, Inc., Japan; Udaka, Juzo
SOURCE: Jpn. Kokai Tokkyo Koho, 38 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003079379	A2	20030318	JP 2001-278534	20010913
WO 2003025182	A1	20030327	WO 2002-JP9155	20020909

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2001-278534 A 20010913

AB This invention relates to a chimeric gene comprising a sequence encoding a fusion protein, wherein the fusion protein comprises: a sequence of a leader peptide of a Bacillus cell wall protein (CWP); a tag sequence for sepn. and purifn. of the fusion protein; a linker sequence; a sequence for enzymic cleavage; and an exogenous growth hormone coding sequence; and its use in recombinant expression of human growth hormone. A promoter and shine-Dalgarno sequence may also be used. Vectors contg. hexahistidine tag and various linker and cleavage sequences were constructed for recombinant expression of human growth hormone in Bacillus brevis.

IT **158760-86-2P**
RL: BPN (Biosynthetic preparation); PRP (Properties); BIOL (Biological study); PREP (Preparation)
(amino acid sequence; fusion protein construct for recombinant prodn. of human growth hormone in Bacillus bacteria)

IT **501070-33-3 501070-34-4**
RL: PRP (Properties)
(unclaimed protein sequence; fusion protein construct for recombinant prodn. of human growth hormone in Bacillus bacteria)

IT **500996-34-9**
RL: PRP (Properties)
(unclaimed sequence; fusion protein construct for recombinant prodn. of human growth hormone in Bacillus bacteria)

L8 ANSWER 31 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:97397 HCAPLUS
DOCUMENT NUMBER: 138:153436
TITLE: Preparation of indole-6-carboxamides and related compounds as hepatitis C viral polymerase inhibitors
INVENTOR(S): Beaulieu, Pierre Louis; Fazal, Gulrez; Goulet, Sylvie; Kukolj, George; Poirier, Martin; Tsantrizos, Youla S.; Jolicoeur, Eric; Gillard, James; Poupart, Marc-Andre; Rancourt, Jean
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 336 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003010141	A2	20030206	WO 2002-CA1128	20020718
WO 2003010141	A3	20030530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003176433	A1	20030918	US 2002-198680	20020718
US 2004024190	A1	20040205	US 2002-198384	20020718

PRIORITY APPLN. INFO.: US 2001-307674P P 20010725
US 2001-338061P P 20011207
OTHER SOURCE(S): MARPAT 138:153436
GI



I



II

AB An isomer, enantiomer, diastereoisomer or tautomer of I (variables defined below; e.g. (E)-3-[4-[2-[[1-(3-cyclohexyl-2-furan-3-yl-1H-indol-6-yl)methanoyl]amino]-2-methylpropanoylamino]phenyl]acrylic acid (shown as

II)), a salt or a deriv. thereof, as inhibitors of HCV NS5B polymerase are claimed. For I: A is O, S, NR1, or CR1; solid line/dotted line combination = single or double bond; R2 = H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, CON(R22)2, NR22C(O)R22 or NR22C(O)NR22; B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3; K is N or CR4; L is N or CR4; M is N or CR4; Y1 is O or S; Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62; and R6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Heterocycle or CR7R8C(:Y2)NR9Q; Y2 is O or S; R9 is H, (C1-6)alkyl, (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl, aryl, Het, (C1-6)alkyl-aryl or (C1-6)alkyl-Het, all of which optionally are substituted with R90; or R9 is covalently bonded to either of R7 or R8 to form a 5- or 6-membered heterocycle; other variables are defined in the claims. About 350 I were tested for inhibitory activity against the hepatitis C virus RNA dependent polymerase (NS5B), e.g. IC50 < 500 nM for II. Forty-five example prepns. of I and intermediates are included. For example, 3-cyclohexyl-2-(furan-3-yl)-1H-indol-6-carboxylic acid (0.16 mmol), (E)-3-[4-(2-Amino-2-methylpropanoylamino)phenyl]acrylic acid Et ester (0.019 mmol) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.32 mmol) were dissolved in DMSO (1 mL); iPr2EtN (0.8 mmol) was added; the mixt. was stirred for 1 h at room temp. then treated with 2.5 N NaOH (0.3 mL) for 1 h at 50.degree. to affect hydrolysis of the cinnamate ester function; the mixt. was then acidified to pH 1 with trifluoroacetic acid and II was isolated by preparative reversed-phase HPLC (0.033 g). Prepns. of the above reactants are also included.

IT **496833-36-4**
RL: PRP (Properties)
(unclaimed protein sequence; prepn. of indole-6-carboxamides and related compds. as hepatitis C viral polymerase inhibitors)

L8 ANSWER 32 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:97396 HCAPLUS
DOCUMENT NUMBER: 138:153435
TITLE: Preparation of indole-6-carboxylic acids and related compounds as hepatitis C viral polymerase inhibitors
INVENTOR(S): Beaulieu, Pierre Louis; Fazal, Gulrez; Kukolj, George; Jolicoeur, Eric; Gillard, James; Poupart, Marc-Andre; Rancourt, Jean
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003010140	A2	20030206	WO 2002-CA1127	20020718
WO 2003010140	A3	20030710		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003176433	A1	20030918	US 2002-198680	20020718
US 2004024190	A1	20040205	US 2002-198384	20020718

PRIORITY APPLN. INFO.: US 2001-307674P P 20010725
US 2001-338061P P 20011207
OTHER SOURCE(S): MARPAT 138:153435
GI



I

AB An isomer, enantiomer, diastereoisomer, or tautomer of I (variables defined below; e.g. 3-cyclohexyl-2-phenylindole-6-carboxylic acid), a salt or a deriv. thereof, as an inhibitor of HCV NS5B polymerase are claimed. For I: A is O, S, NR1, or CR1 (R1 defined within); the dotted/solid line combination = single or double bond; R2 = H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, , CON(R22)2, NR22C(O)R22 or NR22C(O)NR22 (R21 and R22 defined within); B = NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3 (R3 defined within); K = N or CR4 (R4 defined within); L = N or CR4; M = N or CR4; Y1 = O or S; Z = N(R6a)R6 or OR6 (R6a = H or alkyl) or NR61R62 (R61 and R62 defined within). About 50 I were tested for inhibitory activity against the hepatitis C virus RNA dependent polymerase (NS5B), e.g. IC50 < 500 nM for 3-cyclohexyl-1-methyl-2-pyrazinylindole-6-carboxylic acid. Twenty-two example prepns. of I are included. For example, 3-cyclohexyl-2-phenylindole-6-carboxylic acid was prepd. starting from 3-amino-4-iodobenzoic acid via intermediates Me 3-amino-4-iodobenzoate, Me 3-trifluoroacetamido-4-iodobenzoate, 4-phenylethynyl-3-(2,2,2-trifluoroethanoylamino)benzoic acid Me ester, Me 3-(cyclohexenyl)-2-phenylindole-6-carboxylate, and Me 3-cyclohexyl-2-phenylindole-6-carboxylate.

IT **496833-40-0**
RL: PRP (Properties)
(unclaimed protein sequence; prepn. of indole-6-carboxylic acids and related compds. as hepatitis C viral polymerase inhibitors)

L8 ANSWER 33 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:85100 HCAPLUS
DOCUMENT NUMBER: 139:1603
TITLE: A simple Cre-loxP method for chromosomal N-terminal tagging of essential and non-essential Schizosaccharomyces pombe genes
AUTHOR(S): Werler, Petra J. H.; Hartsuiker, Edgar; Carr, Anthony M.
CORPORATE SOURCE: Genome Damage and Stability Centre, School of Biological Sciences, University of Sussex, Sussex, BN1 9RQ, UK
SOURCE: Gene (2003), 304(1-2), 133-141
CODEN: GENED6; ISSN: 0378-1119
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB To facilitate the N-terminal tagging of essential genes at their genomic locus and under control of their own promoters we have developed a series of novel polymerase chain reaction templates. Initially, a 1.8 kb DNA fragment is integrated upstream of the ATG of the gene of interest. This fragment encodes the tag, a loxP site, a selectable marker, an exogenous nmt1 promoter and a second loxP site. In a single homologous integration event, the gene of interest is placed under control of the thiamine regulated nmt1 promoter allowing identification of potential integrants on the basis of phenotype. Subsequently, this integrant strain is transformed

with a plasmid expressing the Cre recombinase. This results in excision of the marker and nmt1 promoter and leaves sequences encoding an in-frame tag at the N-terminus of the gene of interest under the control of its native promoter. We have created TAP-cdc22, TAP-suc22 and TAP-rad50 strains using the N-tagging system, and developed a range of vectors for introducing TAP-, (His)10HA-, (His)6Myc- and EGFP.

IT **534241-68-4**
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence; Cre-loxP method for chromosomal N-terminal tagging of essential and non-essential Schizosaccharomyces pombe genes)

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 34 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:76609 HCAPLUS
DOCUMENT NUMBER: 138:153533
TITLE: Preparation of benzimidazoles as viral polymerase inhibitors
INVENTOR(S): Beaulieu, Pierre Louis; Fazal, Gulrez; Goulet, Sylvie; Kukolj, George; Poirier, Martin; Tsantrizos, Youla S.
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003007945	A1	20030130	WO 2002-CA1129	20020718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003236251	A1	20031225	US 2002-198259	20020718
EP 1411928	A1	20040428	EP 2002-750716	20020718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.: US 2001-306669P P 20010720
US 2001-338324P P 20011207
WO 2002-CA1129 W 20020718

OTHER SOURCE(S): MARPAT 138:153533
GI



I



II

AB Title compds. I [R1 = alkoxy, sulfanyl, carboxy, sulfonamido, amino, carboxamido, etc.; R2 = alkyl, haloalkyl, cycloalkyl, cycloalkenyl, etc.; B, D, X = N, CR5; R5 = H, halo, alkyl, etc.; Z = N, O, NR6; R6 = H, alkyl, cycloalkyl, etc.; R3-4 = H, alkyl, haloalkyl, cycloalkyl, etc.; Y1-2 = O, S; R7 = H, alkyl, cycloalkyl, etc.] are prepd. For instance, Et 4-chloro-3-nitrobenzoate (prepn. given) is treated with cyclohexylamine (DMSO, 60.degree., 5 h) and reduced to the corresponding aniline (MeOH, H2-Pd(OH)2/C). This intermediate is treated with 2-pyridinecarboxaldehyde (DMF, oxone) and the resulting adduct sapond. (NaOH, HOAc) to give II. Example compds. have IC50 in the hepatitis C RNA-dependent polymerase assay of less than 25 .mu.M.

IT **494821-37-3**
RL: PRP (Properties)
(unclaimed protein sequence; prepn. of benzimidazoles as viral polymerase inhibitors)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 35 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:58323 HCAPLUS
DOCUMENT NUMBER: 138:119555
TITLE: System and method of determining proteomic differences
INVENTOR(S): Washburn, Michael; Deciu, Cosmin; Ulasek, Ryan
PATENT ASSIGNEE(S): Syngenta Participations A.-G., Switz.
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006951	A2	20030123	WO 2002-US22320	20020712
WO 2003006951	A3	20030522		

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003068825 A1 20030410 US 2002-195774 20020712
PRIORITY APPLN. INFO.: US 2001-305169P P 20010713
US 2002-359524P P 20020221

AB The present invention relates to a system and methods for identifying differential peptide expression in one or more peptide populations. Each population 109 is labeled with a discernable label and provides a mechanism to resolve mixed peptide populations 130 using mass spectroscopy-based techniques. Spectra 146 produced by the peptide sample are used to interrogate a spectral database in which peptide sequences of known spectra are stored. In addn. to providing sequence information, the methods presented herein may be used to det. qual. and quant. measurements of peptide expression. These measurements may further be used to det. proteomic differences and novel peptide expression. Diagrams describing the app. assembly and operation are given.

IT **444875-74-5**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(system and method of detg. proteomic differences)

IT **158760-86-2 444875-72-3 444875-73-4 444875-75-6 444875-76-7 444875-77-8 444875-78-9 444875-79-0 444875-80-3 444875-81-4 444875-82-5 444875-83-6**
RL: PRP (Properties)
(unclaimed sequence; system and method of detg. proteomic differences)

L8 ANSWER 36 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:833094 HCAPLUS
DOCUMENT NUMBER: 137:346116
TITLE: Conformational assays to detect binding to membrane spanning, signal-transducing proteins
INVENTOR(S): Kobilka, Brian K.; Ghanouni, Pejman; Lee, Tae Weon
PATENT ASSIGNEE(S): The Board of Trustees of the Leland Stanford Junior University, USA
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002086507	A1	20021031	WO 2002-US13250	20020424

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003129649 A1 20030710 US 2001-935061 20010821
PRIORITY APPLN. INFO.: US 2001-286250P P 20010424
US 2001-935061 A 20010821

AB The invention provides methods and compns. for detection of compds. that have activity in modulating activity of membrane-spanning, signal-transducing (MSST) proteins, e.g., agonists, and antagonists. The detection method is based upon detection of a conformational change in a MSST protein upon interaction with a ligand. Conformational change of the MSST protein upon ligand interaction is accomplished by modifying the MSST protein to comprise a conformationally sensitive detectable probe, so that ligand interaction that results in a conformational change in the MSST protein is detected by a change in detectable signal from the detectable probe. The conformationally sensitive detectable probe can be a chem. label (e.g., a fluorophore) or moiety integral to the protein (e.g., a protease cleavage site, or immunodetectable moiety). The conformational assays of the invention provide for high-throughput screening.

IT **474340-82-4 474340-84-6 474340-88-0**
474340-90-4
RL: PRP (Properties)
(unclaimed protein sequence; conformational assays to detect binding to membrane spanning, signal-transducing proteins)

IT **474351-79-6 474351-80-9**
RL: PRP (Properties)
(unclaimed sequence; conformational assays to detect binding to membrane spanning, signal-transducing proteins)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 37 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:754431 HCAPLUS
DOCUMENT NUMBER: 137:274074
TITLE: Recombinant production of polyanionic polymers, and uses thereof as drug carriers for improvement of bioactivity and water-solubility
INVENTOR(S): Leung, David W.; Bergman, Philip A.; Lofquist, Alan; Pietz, Gregory E.; Tompkins, Christopher K.; Waggoner, David W., Jr.
PATENT ASSIGNEE(S): Cell Therapeutics Inc, USA
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077036	A2	20021003	WO 2002-US8614	20020321
WO 2002077036	A3	20040129		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002169125	A1	20021114	US 2002-101487	20020320

PRIORITY APPLN. INFO.: US 2001-277705P P 20010321

AB The invention provides a method for constructing a expression cassette that produce a polyanionic polymer that can be used as drug carriers to improve the bioactivity and water-soly. properties of a drug. The inventive method provides a monodispersed prepn. of a recombinantly-produced polyanionic polymer that can be easily manipulated, such as

lengthened. An active moiety may be chem. or recombinantly joined to a polyanionic polymer to increase its biol. half-life and/or soly. The instant invention also provides a method for targeting the delivery of a polyanionic polymer conjugate or fusion protein to a specific cell type or tissue.

IT **466711-98-8**
RL: PRP (Properties)
(unclaimed sequence; recombinant prodn. of polyanionic polymers, and uses thereof as drug carriers for improvement of bioactivity and water-soly.)

L8 ANSWER 38 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:736381 HCAPLUS
DOCUMENT NUMBER: 137:259337
TITLE: Sequences of myo-inositol oxygenases for the production of glucuronic acids, ascorbic acids, and glucaric acids
INVENTOR(S): Schroeder, William A.; Hicks, Paula M.; McFarlan, Sara C.; Abraham, Timothy W.
PATENT ASSIGNEE(S): Cargill Incorporated, USA
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074926	A2	20020926	WO 2002-US8404	20020319

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-277148P P 20010319

AB The present invention relates generally to methods and materials for producing org. compds. such as myo-inositol, glucuronic acid, glucaric acid, and ascorbic acid. Specifically, the invention provides cells (e.g., bacterial, fungal, and insect cells), methods for culturing cells, isolated nucleic acid mols., and methods and materials for producing various org. compds. The invention is based on the discovery that cells can be genetically manipulated such that they have the ability to produce a desired org. product. The invention also is based on the discovery of efficient metabolic pathways that utilize glucose and/or phytic acid to produce ascorbic acid. Specifically, ascorbic acid can be produced from glucose and/or phytic acid using a metabolic pathway that can convert myo-inositol into glucuronate. In general, such pathways require less enzymic steps than the native metabolic pathways used by plants and animals to produce ascorbic acid from glucose. Any method that can efficiently produce ascorbic acid from a carbon source such as glucose or phytic acid would be useful for large-scale prodn. efforts. In addn., the methods and materials provided herein can be used to produce org. compds. without the need of chem. steps such as an acid treatment at high temp.

IT **463371-73-5P**, Oxygenase, inositol (synthetic human)
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation)
(amino acid sequence; sequences of myo-inositol oxygenases for prodn.

of glucuronic acids, ascorbic acids, and glucaric acids)

L8 ANSWER 39 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:309818 HCAPLUS
DOCUMENT NUMBER: 136:336176
TITLE: Compositions containing DNA, Tat peptide-nucleic acid binder conjugates, and cationic lipids for cell transfections
INVENTOR(S): Hawley-Nelson, Pamela; Lan, Jianqing; Shih, Pojen; Jessee, Joel A.; Schifferli, Kevin P.; Gebeyehu, Gulilat; Ciccarone, Valentina C.; Evans, Krista L.
PATENT ASSIGNEE(S): Life Technologies, Inc., USA
SOURCE: U.S., 108 pp., Cont.-in-part of U.S. 6,051,429.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6376248	B1	20020423	US 1998-39780	19980316
US 6051429	A	20000418	US 1997-818200	19970314
US 2003069173	A1	20030410	US 2001-911569	20010723
US 2003144230	A1	20030731	US 2002-200879	20020723

PRIORITY APPLN. INFO.:
US 1997-818200 A2 19970314
US 1995-477354 B2 19950607
US 1996-658130 A2 19960604
US 1998-39780 A1 19980316
US 2001-911569 A1 20010723

AB The present invention provides compns. useful for transfecting cells comprising nucleic acid complexes with Tat peptide, wherein the peptide is covalently coupled to a nucleic acid-binding group, and cationic lipids as transfection agents. Inclusion of peptides in transfection compns. or covalent attachment of peptides to transfection agents results in enhanced transfection efficiency. Methods for the prepn. of transfection compns. and methods of using these transfection compns. as intracellular delivery agents are also disclosed.

IT **416230-90-5**
RL: PRP (Properties)
(unclaimed protein sequence; compns. contg. DNA, Tat peptide-nucleic acid binder conjugates, and cationic lipids for cell transfections)

IT **264236-19-3**
RL: PRP (Properties)
(unclaimed sequence; compns. contg. DNA, Tat peptide-nucleic acid binder conjugates, and cationic lipids for cell transfections)

REFERENCE COUNT: 157 THERE ARE 157 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 40 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:51438 HCAPLUS
DOCUMENT NUMBER: 136:118447
TITLE: Preparation of benzimidazolecarboxylates and related compounds as viral polymerase inhibitors
INVENTOR(S): Beaulieu, Pierre Louis; Fazal, Gulrez; Gillard, James; Kukolj, George; Austel, Volkhard
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004425	A2	20020117	WO 2001-CA989	20010704
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002065418	A1	20020530	US 2001-898297	20010703
US 6448281	B2	20020910		
EP 1301487	A2	20030416	EP 2001-951274	20010704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004502761	T2	20040129	JP 2002-509292	20010704
US 6479508	B1	20021112	US 2001-995099	20011127
WO 2002070739	A2	20020912	WO 2002-CA323	20020306
WO 2002070739	A3	20030530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1370682	A2	20031217	EP 2002-712681	20020306
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003232816	A1	20031218	US 2002-238282	20020910

PRIORITY APPLN. INFO.:

US 2000-216084P P 20000706
US 2001-274374P P 20010308
US 2001-281343P P 20010405
US 2001-898297 A3 20010703
WO 2001-CA989 W 20010704
US 2001-995099 A3 20011127
WO 2002-CA323 W 20020306

OTHER SOURCE(S): MARPAT 136:118447

GI



I

AB Title compds. [I; X = CH, N; Y = O, S; Z = OH, NH2, NMeR3, NHR3, OR3, 5-6 membered (substituted) heterocyclyl; A = N, COR7, CR5; R5 = H, halo, alkyl; R7 = H, alkyl; X and A are not both N; R6 = H, halo, alkyl, OR7; R7 = H , alkyl; R1 = (substituted) hetero(bi)cyclyl, Ph, phenylalkyl, alkenyl, phenylalkenyl, cycloalkyl, alkyl, CF3; R2 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, bicycloalkyl, adamantyl, Ph, pyridyl; R3 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, alkenyl,

cycloalkylalkenyl, arylalkenyl, dialkylamino, heterocyclyl, etc.; n = 0, 1], were prepd. Thus, Me 3-amino-4-cyclohexylaminobenzoate (prepn. given), 2-pyridinecarboxaldehyde, and Oxone were stirred in DMF to give 80% Et 1-cyclohexyl-2-pyridin-2-yl-1H-benzimidazole-5-carboxylate, which was sapond. with aq. NaOH in MeOH to give 91% 1-cyclohexyl-2-pyridin-2-yl-1H-benzimidazole-5-carboxylic acid. The latter inhibited hepatitis C virus RNA dependent polymerase (NS5B) with IC50 = 1-5 .mu.M.

IT **390883-37-1**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; prepn. of benzimidazolecarboxylates and related compds. as viral polymerase inhibitors)

L8 ANSWER 41 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:923981 HCAPLUS
DOCUMENT NUMBER: 136:50271
TITLE: Mutant nuclear inclusion proteinase NIa with reduced self-cleavage activity
INVENTOR(S): Doudna, Jennifer A.; Lucast, Louise J.; Batey, Robert T.
PATENT ASSIGNEE(S): Yale University, USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096539	A2	20011220	WO 2001-US18620	20010611
WO 2001096539	A3	20020516		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2004072179	A1	20040415	US 2003-343766	20031009

PRIORITY APPLN. INFO.:

US 2000-211535P	P	20000615
WO 2001-US18620	W	20010611

AB The present invention provides a mutant 27-kDa NIa proteinase having reduced self-cleavage activity relative to the self-cleavage activity of its wild-type proteinase. The mutant has the same substrate cleavage activity as the wild-type proteinase but is more stable than the wild-type proteinase. Wild-type well as mutant, histidine-tagged 27-kDa NIa constructs can be induced to express >95% of the proteinase in the insol. fraction. A novel method of single-column denaturing purifn. of the insol. fraction followed by renaturation of the peptide yields up to 10-fold as much active 27-kDa NIa proteinase as the sol. prepn. reported by others. The serine-219 to asparagine mutation in the mutant form of the 27-kDa NIa proteinase (from tobacco etch virus) significantly inhibits self-cleavage activity, allowing the increased yields of full-length, fully active 27-kDa NIa proteinase, from either sol. or insol. prepns. Long-term storage of NIa stocks at -20.degree., and short-term storage at 4.degree., is possible. The present invention also provides a method of obtaining large quantities of active 27-kDa NIa proteinase for use as a tool for purifn. of other proteins.

IT **158760-86-2**
RL: PRP (Properties)
(unclaimed sequence; mutant nuclear inclusion proteinase NIa with

reduced self-cleavage activity)

L8 ANSWER 42 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:816893 HCAPLUS
DOCUMENT NUMBER: 135:353893
TITLE: Internal de novo initiation sites of the NS5B RNA dependent RNA polymerase of hepatitis C virus NS5B and uses thereof
INVENTOR(S): Pellerin, Charles; Kukolj, George
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083736	A2	20011108	WO 2001-CA580	20010420
WO 2001083736	A3	20020801		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2001055756	A1	20011227	US 2001-838386	20010420
EP 1278837	A2	20030129	EP 2001-927534	20010420
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-198793P P 20000421
WO 2001-CA580 W 20010420

AB The present invention provides a de novo initiation site comprising a polypyrimidine tract having a cytidylate nucleotide or a polycytidylate (poly C) cluster located therein or adjacent thereto. This site provides a RNA template for assessing in vitro RNA dependent RNA polymerase (RdRp) activity of flavivirus. Particularly, the invention relates to de novo initiation sites of the NS5B protein of the hepatitis C virus and methods for identifying specific inhibitors thereof. To further define the nature of de novo initiation from the 3'-UTR, several distinct 3'-UTR's that harbor the conserved terminal 98 nucleotides, but have poly U/U-C tracts of different length were isolated and characterized. Reconstitution of de novo initiation by the mature NS5B with the different 3'-UTR RNA substrates revealed distinctively sized products that are consistent with internal initiation at specific sites within the polypyrimidine tract. These sites were mapped by demonstrating that nucleotide substitutions of the cytidylate residues in the poly U/U-C template affect the generation of specific products of the de novo initiation reaction. Moreover, initiation within the poly U/U-C template is also primed by GTP and an assay that evaluates inhibitors of this reaction as potential HCV therapeutics is claimed.

IT **372211-82-0**
RL: PRP (Properties)
(unclaimed protein sequence; internal de novo initiation sites of the NS5B RNA dependent RNA polymerase of hepatitis C virus NS5B and uses thereof)

L8 ANSWER 43 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:159101 HCAPLUS

DOCUMENT NUMBER: 135:299437
TITLE: Recombinant Phycobiliproteins
AUTHOR(S): Cai, Yuping A.; Murphy, John T.; Wedemayer, Gary J.; Glazer, Alexander N.
CORPORATE SOURCE: Department of Molecular and Cell Biology, University of California, Berkeley, CA, 94720-3200, USA
SOURCE: Analytical Biochemistry (2001), 290(2), 186-204
CODEN: ANBCA2; ISSN: 0003-2697
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A family of specific cloning vectors was constructed to express in the cyanobacterium Anabaena sp. PCC7120 recombinant C-phycocyanin subunits with one or more different tags, including the 6.times.His tag, oligomerization domains, and the streptavidin-binding Strep2 tag. Such tagged .alpha. or .beta. subunits of Anabaena sp. PCC7120 C-phycocyanin formed stoichiometric complexes in vivo with appropriate wild-type subunits to give constructs with the appropriate oligomerization state and normal posttranslational modifications and with spectroscopic properties very similar to those of unmodified phycocyanin. All of these constructs were incorporated in vivo into the rod substructures of the light-harvesting complex, the phycobilisome. The C-terminal 114-residue portion of the Anabaena sp. PCC7120 biotin carboxyl carrier protein (BCCP114) was cloned and overexpressed and was biotinylated up to 20% in Escherichia coli and 40% in wild-type Anabaena sp. His-tagged phycocyanin .beta.-BCCP114 constructs expressed in Anabaena sp. were >30% biotinylated. In such recombinant phycocyanins equipped with stable trimerization domains, >75% of the fusion protein was specifically bound to streptavidin- or avidin-coated beads. Thus, the methods described here achieve in vivo prodn. of stable oligomeric phycobiliprotein constructs equipped with affinity purifn. tags and biospecific recognition domains usable as fluorescent labels without further chem. manipulation. (c) 2001 Academic Press.

IT **366024-87-5 366462-62-6**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; recombinant Phycobiliproteins)

REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 44 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:12641 HCAPLUS
DOCUMENT NUMBER: 134:81787
TITLE: sequence and cloning of human Tankyrase2 with anti-neoplastic therapeutic applications for those diseases associated with poly(ADP-ribose) polymerase activity
INVENTOR(S): Christenson, Erik; Demaggio, Anthony J.; Goldman, Phyllis S.; Mcelligott, David L.
PATENT ASSIGNEE(S): Icos Corporation, USA
SOURCE: PCT Int. Appl., 242 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000849	A1	20010104	WO 2000-US17827	20000628

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1192259	A1	20020403	EP 2000-943257	20000628
JP 2003503062	T2	20030128	JP 2001-506841	20000628
US 2003190739	A1	20031009	US 2002-199937	20020722

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: US 1999-141582P P 19990629
US 2000-606035 B1 20000628
WO 2000-US17827 W 20000628

AB The invention provides novel tankyrase polypeptides designated tankyrase2, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, and host cells transformed with the expression constructs. Also provided are methods for producing the tankyrase2 polypeptides, antibodies that are immunoreactive with the tankyrase2 polypeptides. In addn., there are provided methods for identifying specific binding partners of tankyrase2, and more particularly methods for identifying binding partners that modulate biol. activity of tankyrase2. Methods of modulating biol. activity of tankyrase2 in vitro and in vivo are also provided. Administration of the tankyrase2 protein can treat a medical condition mediated by poly(ADP-ribose) polymerase activity and growth of neoplastic tissue. Prodn. of recombinant viral stocks and protein purifn. are also described.

IT **316202-99-0**
RL: PRP (Properties)
(unclaimed protein sequence; sequence and cloning of human Tankyrase2 with anti-neoplastic therapeutic applications for those diseases assocd. with poly(ADP-ribose) polymerase activity)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 45 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:900783 HCAPLUS
DOCUMENT NUMBER: 134:53138
TITLE: Human poly(ADP-ribose) polymerase 2 and its encoding cDNA sequence and screening and therapeutic uses
INVENTOR(S): Christenson, Erik; Demaggio, Anthony J.; Goldman, Phyllis S.; McElligott, David L.
PATENT ASSIGNEE(S): Icos Corporation, USA
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000077179	A2	20001221	WO 2000-US16629	20000616
WO 2000077179	A3	20010222		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1192258 A2 20020403 EP 2000-942875 20000616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
JP 2003502033 T2 20030121 JP 2001-503624 20000616
US 6599727 B1 20030729 US 2000-596248 20000616
US 2003170859 A1 20030911 US 2003-369378 20030219
PRIORITY APPLN. INFO.: US 1999-139543P P 19990616
US 2000-596248 A1 20000616
WO 2000-US16629 W 20000616

AB The invention provides a novel human poly(ADP-ribose) polymerase (hPARP2) polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, and host cells transformed with the expression constructs. Human cDNA encoding hPARP2 was identified using the nucleotide sequence of mouse parp2 to search the NCBI expressed sequence tag (EST) database. Also provided are methods for producing the hPARP2 polypeptides, and antibodies that are immunoreactive with the hPARP2 polypeptides. In addn., there are provided methods for identifying specific binding partners of hPARP2, and more particularly methods for identifying binding partners that modulate biol. activity of hPARP2. Methods of modulating biol. activity of hPARP2 in vitro and in vivo are also provided.

IT **313289-46-2 313289-58-6**
RL: PRP (Properties)
(unclaimed protein sequence; human poly(ADP-ribose) polymerase 2 and its encoding cDNA sequence and screening and therapeutic uses)

L8 ANSWER 46 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:688263 HCAPLUS
DOCUMENT NUMBER: 133:271617
TITLE: A novel polypeptide isolated from Haemonchus contortus for development of anthelmintic agents
INVENTOR(S): Savin, Keith William; Cook, Vanessa Renee; Chen, Yaping; Sexton, Jennifer Louise; Apos, Esther; Wilson, Lachlan Robert; Griffiths, Tamarae Marilyn; Newton, Susan Elizabeth
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Agriculture Victoria Services Pty. Ltd.
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056763	A1	20000928	WO 2000-AU210	20000316

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: AU 1999-9297 A 19990318

AB The present invention relates generally to a novel polypeptide and its derivs., homologues, and analogs which polypeptide is obtainable from a helminth, and more particularly a nematode, or produced by recombinant or chem. synthetic means. The polypeptide and its derivs., homologues and analogs of the present invention may be used in the manuf. of a compn. which is capable of inducing protection in helminth-susceptible animals to

infection by said helminth and/or to reduce, inhibit or otherwise retard growth, viability and/or egg fecundity of said helminth and/or to ameliorate the symptoms of helminth infection. Another aspect of the present invention contemplates a method of controlling helminth, and more particularly nematode, infection, growth, viability and/or egg fecundity and/or ameliorating the symptoms of helminth infection by the administration of a polypeptide from said helminth or a deriv., homolog, or analog of said polypeptide.

IT **298200-39-2**
RL: PRP (Properties)
(unclaimed protein sequence; novel polypeptide isolated from Haemonchus contortus for development of anthelmintic agents)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 47 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:628249 HCAPLUS
DOCUMENT NUMBER: 133:218507
TITLE: Genetic engineering of cells resistant to toxic genes and their uses in cloning
INVENTOR(S): Hartley, James L.; Brasch, Michael A.; Temple, Gary F.
PATENT ASSIGNEE(S): Life Technologies, Inc., USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000052141	A1	20000908	WO 2000-US5246	20000302
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1159402	A1	20011205	EP 2000-912085	20000302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537800	T2	20021112	JP 2000-602753	20000302
US 2004053412	A1	20040318	US 2003-396696	20030326

PRIORITY APPLN. INFO.:
US 1999-122392P P 19990302
US 2000-518188 B1 20000302
WO 2000-US5246 W 20000302

AB The present invention relates to cells and cell strains that are resistant to the killing effects of one or more toxic genes, particularly those that kill hosts in the absence of a suppressing function, e.g. kicB or ccdB. The host cells may comprise one or more suppression mutations, such as deletional or insertional mutations in gyrA, endA or recA, or combinations thereof (particularly gyrA/endA or gyrA/recA), which allow cell strains carrying the one or more suppression mutations to survive the presence and/or expression of one or more toxic genes within their genome or in extrachromosomal genetic elements within the host cell. Preferred host cell strains include prokaryotic host cells, particularly specified strains of Escherichia coli contg. the gyrA462 mutation and/or one or more addnl. mutations, such as DB3, DB3.1, DB4, and DB5. Strain DB3 contains the gyrA462 and endA mutations, and a complete deletion of the recA gene. Strain DB3.1 contains the same gyrA462, endA, and recA mutations as DB3,

and is tetracycline-sensitive due to deletion of the tetr gene. Strain DB4 contains the gyrA462 and endA mutations, a deletion at base 1398 of the recA gene, and the Tn10 transposon; finally, strain DB5 contains the same gyrA462, endA and recA mutations as DB4, and is tetracycline sensitive. The host cells of the invention are useful in producing recombinant genetic constructs, particularly cDNAs and cDNA libraries, via traditional genetic engineering techniques or via recombinational cloning using engineered recombination sites. The host cells are also useful in cloning and propagation of toxic genes that act upon DNA gyrase, such as ccdB.

IT **291276-58-9**
RL: PRP (Properties)
(unclaimed sequence; genetic engineering of cells resistant to toxic genes and their uses in cloning)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 48 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:628153 HCAPLUS
DOCUMENT NUMBER: 133:233572
TITLE: Recombinational GATEWAY cloning system for nucleic acid molecules
INVENTOR(S): Hartley, James L.; Brasch, Michael A.; Temple, Gary F.; Cheo, David
PATENT ASSIGNEE(S): Life Technologies, Inc., USA
SOURCE: PCT Int. Appl., 459 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000052027	A1	20000908	WO 2000-US5432	20000302
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1173460	A1	20020123	EP 2000-914799	20000302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537790	T2	20021112	JP 2000-602252	20000302

PRIORITY APPLN. INFO.:
US 1999-122389P P 19990302
US 1999-126049P P 19990323
US 1999-136744P P 19990528
WO 2000-US5432 W 20000302

AB The present invention relates generally to compns. and methods for use in recombinational cloning of nucleic acid mols. In particular, the invention relates to nucleic acid mols. encoding one or more recombination sites or portions thereof, to nucleic acid mols. comprising one or more of these recombination site nucleotide sequences and optionally comprising one or more addnl. phys. or functional nucleotide sequences. In particular, the invention relates to use of the recombination sites attB1, attB2, attP1, attP2, attL1, attL2, attR1, attR2, and fragments, mutants, variants and derivs. thereof. The invention also relates to the use of these compns. in methods for recombinational cloning of nucleic acids, in vitro and in vivo , to provide chimeric DNA mols. that have particular

characteristics and/or DNA segments. Two reactions constitute the recombinational cloning system of the present invention, referred to herein as the "GATEWAY Cloning System". The first of these reactions, the LR Reaction (or Destination) is a recombination reaction between an Entry vector or clone and a Destination Vector, mediated by a cocktail of recombination proteins such as the GATEWAY LR Clonase Enzyme mix (integrase, excisionase Xis, and IHF or integration host factor). This reaction transfers nucleic acid mols. of interest from the Entry Clone to an Expression Vector, to create and Expression clone. The nucleic acid mol. of interest in an Expression Clone is flanked by the small attB1 and attB2 sites, and the orientation and reading frame of the nucleic acid mol. of interest are maintained throughout the subcloning. The second major pathway is the BP Reaction (or the Entry Reaction or Gateward Reaction), which recombines an Expression Clone with a Donor Plasmid and transfers the nucleic acid mol. of interest in the Expression Clone into an Entry Vector, to produce a new Entry Clone, and then can be transferred into new Expression Vectors.

IT **292605-73-3**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(recombinational GATEWAY cloning system for nucleic acid mols.)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 49 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:426453 HCAPLUS
DOCUMENT NUMBER: 133:218962
TITLE: Controlled Intracellular Processing of Fusion Proteins by TEV Protease
AUTHOR(S): Kapust, Rachel B.; Waugh, David S.
CORPORATE SOURCE: Program in Structural Biology, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD, 21702-1201, USA
SOURCE: Protein Expression and Purification (2000), 19(2), 312-318
CODEN: PEXPEJ; ISSN: 1046-5928
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Here we describe a method for controlled intracellular processing (CIP) of fusion proteins by tobacco etch virus (TEV) protease. A fusion protein contg. a TEV protease recognition site is expressed in Escherichia coli cells that also contain a TEV protease expression vector. The fusion protein vector is an IPTG-inducible ColE1-type plasmid, such as a T7 or tac promoter vector. In contrast, the TEV protease is produced by a compatible p15A-type vector that is induced by tetracyclines. Not only is the TEV protease regulated independently of the fusion protein, but its expression is highly repressed in the absence of inducer. Certain fusion partners have been shown to enhance the yield and soly. of their passenger proteins. When CIP is used as a purifn. step, it is possible to take advantage of these characteristics while both eliminating the need for large amts. of pure protease at a later stage and possibly simplifying the purifn. process. Addnl., we have obsd. that in some cases the timing of intracellular proteolysis can affect the soly. of the cleaved passenger protein, allowing it to be directed to either the sol. or the insol. fraction of the crude cell lysate. This method also makes it possible to quickly gauge the efficiency of proteolysis in vivo, before protein purifn. has begun and in vitro processing is attempted. (c) 2000 Academic Press.

IT **158760-86-2**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(tobacco etch virus protease recognition site engineered between

maltose binding protein and a passenger protein)
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 50 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:254039 HCAPLUS
DOCUMENT NUMBER: 132:289590
TITLE: Peptide-enhanced cationic lipid transfections
INVENTOR(S): Hawley-Nelson, Pamela; Lan, Jianqing; Shih, Pojen; Jessee, Joel A.; Schifferli, Kevin P.; Gebeyehu, Gulilat
PATENT ASSIGNEE(S): Life Technologies, Inc., USA
SOURCE: U.S., 103 pp., Cont.-in-part of U.S. 5,736,392. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6051429	A	20000418	US 1997-818200	19970314
US 5736392	A	19980407	US 1996-658130	19960604
WO 9840502	A1	19980917	WO 1998-US5232	19980316
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9865622	A1	19980929	AU 1998-65622	19980316
EP 1007699	A1	20000614	EP 1998-911737	19980316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001517939	T2	20011009	JP 1998-539899	19980316
US 6376248	B1	20020423	US 1998-39780	19980316
US 2003144230	A1	20030731	US 2002-200879	20020723

PRIORITY APPLN. INFO.:
US 1995-477354 B2 19950607
US 1996-658130 A2 19960604
US 1997-818200 A 19970314
US 1998-39780 A1 19980316
WO 1998-US5232 W 19980316
US 2001-911569 A1 20010723

AB The present invention provides compns. useful for transfecting eukaryotic cells comprising nucleic acid complexes with peptides, wherein the peptide is optionally covalently coupled to a nucleic acid-binding group, and cationic lipids or dendrimers as transfection agents. The invention also provides transfection compns. in which a peptide is covalently linked to the transfection agent (lipid, cationic lipid or dendrimer). Inclusion of peptides or modified-peptides in transfection compns. or covalent attachment of peptides to transfection agents results in enhanced transfection efficiency. Methods for the prepn. of transfection compns. and methods of using these transfection compns. as intracellular delivery agents and extracellular targeting agents are also disclosed.

IT **264266-32-2**
RL: PRP (Properties)
(unclaimed protein sequence; peptide-enhanced cationic lipid transfections)

IT **264236-19-3**
RL: PRP (Properties)
(unclaimed sequence; peptide-enhanced cationic lipid transfections)

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 51 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:722790 HCAPLUS
DOCUMENT NUMBER: 131:347487
TITLE: Chimeric genes for cell wall protein fragment-containing fusion proteins and production of proteins with recombinant Bacillus
INVENTOR(S): Sato, Seiji; Higashikuni, Naohiko; Kudo, Toshiyuki; Kondo, Masaakii
PATENT ASSIGNEE(S): Itoham Foods Inc., Japan; Udaka, Shigezo
SOURCE: Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 955370	A2	19991110	EP 1999-302514	19990331
EP 955370	A3	20001220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2001021515	A1	20010913	US 1999-280030	19990326
US 6506595	B2	20030114		
JP 11341991	A2	19991214	JP 1999-89488	19990330
JP 3313083	B2	20020812		
JP 2003000283	A2	20030107	JP 2002-108410	19990330

PRIORITY APPLN. INFO.: JP 1998-87339 A 19980331
JP 1999-89488 A3 19990330

AB This invention relates to a chimeric gene comprising a sequence encoding a fusion protein, wherein the fusion protein comprises: a sequence of a signal peptide of a Bacillus cell wall protein; a tag sequence for sepn. and purifn. of the fusion protein; a linker sequence; a sequence for chem. or enzymic cleavage; and an exogenous polypeptide sequence, said sequences being linked in order, said signal peptide, tag and linker being optional sequences. The nucleotide sequence encoding a fusion protein is ligated to the 3'-end of a nucleic acid sequence comprising a Bacillus promoter region. The invention also relates to a vector comprising the DNA; to a bacterium belonging to the genus Bacillus comprising the vector; and to a process for prepn. of a useful polypeptide by culture of the bacterium. Thus, the prodn. with B. brevis of human proinsulin, somatotropin, and glucagon by the above process was demonstrated. The fusion proteins comprised the signal peptide of the cell wall protein, 10-20 amino acids of the mature cell wall protein, a hexahistidine tag, a chem.- or protease-cleavable linker, and the desired protein.

IT **250232-55-4P**
RL: BPN (Biosynthetic preparation); PRP (Properties); BIOL (Biological study); PREP (Preparation)
(amino acid sequence; chimeric genes for cell wall protein fragment-contg. fusion proteins and prodn. of proteins with recombinant Bacillus)

L8 ANSWER 52 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:222965 HCAPLUS
DOCUMENT NUMBER: 130:251215
TITLE: Catalytic antibodies and a method of producing same
INVENTOR(S): Koentgen, Frank; Suess, Gabriele Maria; Tarlinton, David Mathew; Treutlein, Herbert Rudolf
PATENT ASSIGNEE(S): Amrad Operations Pty. Ltd., Australia
SOURCE: PCT Int. Appl., 101 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915563	A1	19990401	WO 1998-AU783	19980918
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2304365	AA	19990401	CA 1998-2304365	19980918
AU 9891467	A1	19990412	AU 1998-91467	19980918
AU 744911	B2	20020307		
EP 1015494	A1	20000705	EP 1998-943578	19980918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
GB 2345694	A1	20000719	GB 2000-9758	19980918
GB 2345694	B2	20020717		
NZ 515603	A	20030429	NZ 1998-515603	19980918
US 6590080	B1	20030708	US 2000-509031	20000609
US 2003148484	A1	20030807	US 2003-345618	20030116

PRIORITY APPLN. INFO.:
AU 1997-9306 A 19970919
WO 1998-AU783 W 19980918
US 2000-509031 A3 20000609

AB The present invention relates generally to a growth factor precursor and its use to select prodn. of antigen specific catalytic antibodies. Such catalytic antibodies are produced following B cell activation and proliferation induced by catalytic cleavage products of a target antigen portion of the growth factor precursor of the present invention. A particularly useful form of the growth factor precursor is as a nucleic acid vaccine. The nucleic acid vaccine of the present invention preferably further comprises a mol. adjuvant. Another aspect of the present invention comprises a growth factor precursor in multimeric form. The growth factor precursor of the present invention is useful for generating catalytic antibodies for both therapeutic, diagnostic and industrial purposes, esp. for treating rheumatoid arthritis, AIDS and Alzheimer's disease and others. Thus, pASK75 encoding ompA signal sequence and LHL was constructed and expressed in Escherichia coli, and LHL was purified over a human IgG affinity column. Similarly, LHL.seq contg. N-terminal FLAG epitope (DYKDDDDK) and C-terminal strep-tag (AWRHPQFGG) was generated, while the FLAG epitope was added to facilitate the secretion of LHL.seq and strep-tag was added for purifn. by streptavidin column. TLHL comprising FLAG-kappa-linker-tobacco etch virus protease (TEV)-LHL-strep-tag was also generated and CATAB-TEV was assembled from TLHL and kappa by PCR. B cell proliferation and activation, B7-1 expression, MHC class II induction, detection of CATAB-specific catalytic antibodies in serum, OMP-induced multimerization, design of novel multimeric mitogen, etc. were tested with the prepd.

IT **197923-71-0 197923-73-2 221650-12-0**, Catalytic antibody ccMTLgL (synthetic)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; prepn. of recombinant growth factor precursor comprising B or T cell surface mol., antigen cleavable by a catalytic antibody and Ig light or heavy chain domains for diagnosis/treatment and industrial purposes)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 53 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:672386 HCAPLUS
DOCUMENT NUMBER: 129:271524
TITLE: Use of gram-positive bacteria to express recombinant proteins
INVENTOR(S): Darzins, Aldis; Whitehead, Stephen; Hruby, Dennis; Fischetti, Vincent A.
PATENT ASSIGNEE(S): Siga Pharmaceuticals, Inc., USA
SOURCE: U.S., 23 pp., Cont.-in-part of U.S. Ser. No. 735,670. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5821088	A	19981013	US 1995-472244	19950607
US 5616686	A	19970401	US 1994-280390	19940726
CA 2224172	AA	19961219	CA 1996-2224172	19960606
WO 9640943	A1	19961219	WO 1996-US9965	19960606
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
AU 9663310	A1	19961230	AU 1996-63310	19960606
AU 711985	B2	19991028		
EP 832252	A1	19980401	EP 1996-922435	19960606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1192245	A	19980902	CN 1996-195892	19960606
JP 2000512121	T2	20000919	JP 1997-502117	19960606
US 5786205	A	19980728	US 1996-735670	19961017
FI 9704432	A	19980202	FI 1997-4432	19971205

PRIORITY APPLN. INFO.:

US 1990-522440	A1	19900511
US 1991-742199	A1	19910805
US 1991-814323	A1	19911223
US 1992-942432	A1	19920909
US 1993-46495	A1	19930408
US 1994-280390	A1	19940726
US 1996-735670	A2	19961017
US 1992-902432	B1	19920618
US 1995-472244	A	19950607
WO 1996-US9965	W	19960606

AB A novel system is provided for cloning and expression of genes in gram-pos. bacteria. The expression system is based on the finding that many gram-pos. bacteria sort proteins to their cell surface through cis-acting N-terminal signal sequences and C-terminal anchor regions. In particular, the cell sorting signals of the streptococcal M6 protein, a well-known surface mol., are used to construct a gram-pos. expression system, designated SPEX (Streptococcal Protein Expression). Expression is achieved by cloning the gene of interest into an appropriate SPEX cassette which is then stably introduced into a bacterial host, such as the human commensal Streptococcus gordonii. Depending on the SPEX vector used, recombinant proteins can be anchored to the cell wall prior to release by specific endoproteolytic cleavage or secreted into the culture medium during bacterial growth. The use of host bacteria lacking extracellular proteases should protect secreted proteins from proteolytic degrdn.

Several expression vectors in this system also produce specifically-tagged recombinant proteins which allows for a one-step purifn. of the resulting product.

IT **158760-86-2**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(proteolytic cleavage site; use of Gram-pos. bacteria to express recombinant proteins)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 54 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:650373 HCAPLUS
DOCUMENT NUMBER: 127:328387
TITLE: Precursors of catalytic antibodies
INVENTOR(S): Koentgen, Frank; Suess, Gabriele Maria; Tarlinton, David Mathew; Treutlein, Herbert Rudolf
PATENT ASSIGNEE(S): Amrad Operations Pty. Ltd., Australia
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9735887	A1	19971002	WO 1997-AU194	19970326
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2249455	AA	19971002	CA 1997-2249455	19970326
AU 9721434	A1	19971017	AU 1997-21434	19970326
AU 731580	B2	20010405		
ZA 9702620	A	19971120	ZA 1997-2620	19970326
GB 2326643	A1	19981230	GB 1998-20966	19970326
GB 2326643	B2	20000927		
EP 935612	A1	19990818	EP 1997-913981	19970326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6043069	A	20000328	US 1997-828741	19970326
JP 2000507105	T2	20000613	JP 1997-533873	19970326
US 6326179	B1	20011204	US 1998-160567	19980925
US 6521741	B1	20030218	US 2000-710299	20001109

PRIORITY APPLN. INFO.:

AU 1996-8951	A	19960326
AU 1997-5375	A	19970227
US 1997-828741	A1	19970326
WO 1997-AU194	W	19970326
US 1998-160567	A3	19980925

AB The invention is directed to growth factors or precursors of catalytic antibodies comprising a B-cell surface mol. binding portion, which can induce B-cell mitogenesis. The preferred B-cell surface mol. binding portions are the Ig binding mols. of protein L from Peptostreptococcus magnus, protein A, protein G and protein H. The growth factor having an ability to induce B-cell mitogenesis can be further linked to a target antigen to which catalytic antibodies are sought. B-cell mitogenesis is then dependent on the catalytic cleavage of the antigen portion of the growth factor by catalytic antibodies on the surface of B cells. The

method of the present invention is useful for generating catalytic antibodies for both therapeutic and diagnostic purposes. Vector pASK75 expressing growth factor protein LHL contg. P. magnus protein L and hen egg lysozyme was prepd. and expressed in Escherichia coli, and LHL was purified. A form of LHL protein carrying the N-terminal FLAG epitope and the C-terminal strep-tag was generated and tested for B cell mitogenic activity. Similarly, the growth factor precursor CATAB comprises a tumor necrosis factor flanked LHL with the variable region from an Ig .kappa. or .lambda. light chain further masking the B surface Ig binding domain of the L mols. TLHL comprises a variable .kappa. light chain linked to the N-terminus of an amino acid linker sequence comprising the tobacco etch virus protease cleavage site which is in turn linked to LHL.

IT **197923-71-0P 197923-73-2P**
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; recombinant growth factor comprising B cell surface mol. binding peptide)

L8 ANSWER 55 OF 55 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:673861 HCAPLUS
DOCUMENT NUMBER: 121:273861
TITLE: Fusion proteins including a cleavage site recognized by a plant virus protease
INVENTOR(S): Johnston, Stephen A.; Dougherty, William G.
PATENT ASSIGNEE(S): University of Texas System, USA; Oregon State University
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9418331	A2	19940818	WO 1994-US1176	19940131
WO 9418331	A3	19941013		
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5532142	A	19960702	US 1993-21603	19930212
AU 9461322	A1	19940829	AU 1994-61322	19940131
EP 682709	A1	19951122	EP 1994-907952	19940131
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: US 1993-21603 19930212
WO 1994-US1176 19940131

AB Methods for the sepn. of the individual moieties of a fusion protein by manufg. them with a linker that can be cleaved with a plant virus proteinase, e.g. from tobacco etch virus, are described. The selectivity of these proteinases means that they can be used in the presence of inhibitors of less specific proteinases to cleave fusion proteins that include a proteolytically labile moiety. Vectors and hosts useful for overproducing plant virus proteinases are also described. The tobacco etch virus NIa proteinase was manufd. as a fusion product with glutathione-S-transferase or other affinity labels by expression of the gene in Escherichia coli. The use of the proteinase to specifically and efficiently cleave a small (34 amino acid) peptide derived from the GAL4 protein from a fusion protein with glutathione-S-transferase is demonstrated.

IT **158760-86-2**
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological

study); USES (Uses)
(amino acid sequence; fusion proteins including a cleavage site recognized by a plant virus protease)

=> select hit rn l8 1-55
E1 THROUGH E101 ASSIGNED

=> fil reg
FILE 'REGISTRY' ENTERED AT 10:00:13 ON 29 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2004 HIGHEST RN 677274-15-6
DICTIONARY FILE UPDATES: 27 APR 2004 HIGHEST RN 677274-15-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
=>

=> d his l9-l13

(FILE 'HCAPLUS' ENTERED AT 09:59:32 ON 29 APR 2004)
SELECT HIT RN L8 1-55

FILE 'REGISTRY' ENTERED AT 10:00:13 ON 29 APR 2004
L9 101 S E1-E101
L10 101 S L1 AND L9
L13 35 S L10 AND SQL<=100

=> d .seq l13 1-35

L13 ANSWER 1 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **670225-85-1** REGISTRY
CN Glycine, L-methionylglycyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-.alpha.-aspartyl-L-tyrosyl-L-.alpha.-aspartyl-L-isoleucyl-L-prolyl-L-threonyl-L-threonyl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 48: PN: US20040053384 SEQID: 48 unclaimed sequence
SQL **23**
RN **670225-85-1** REGISTRY
SQL **23**

SEQ 1 MGHHHHHHHD YDIPTTENLY FQG
==== ===
HITS AT: 17-23

REFERENCE 1: 140:249011

L13 ANSWER 2 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **663972-01-8** REGISTRY
CN Peptide, (Met-Ala-Asx-Pro-Asn-Asn-Asn-Asn-Asn-Asn-Asn-Asn-Asn-Asn-Leu-Gly-Ile-Glu-Gly-Arg-Glu-Asn-Leu-Tyr-Phe-Gln-Gly-His-His-His-His-His-His-Glu-Asn-Arg) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 17: PN: WO2004016220 FIGURE: 20 unclaimed sequence
SQL **36**
RN **663972-01-8** REGISTRY
SQL **36**

SEQ 1 MABPNNNNNN NNNNLGIEGR ENLYFQGHHH HHHENR
=======
HITS AT: 21-27

REFERENCE 1: 140:212978

L13 ANSWER 3 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **631936-75-9** REGISTRY
CN 23: PN: EP1369483 FIGURE: 4 unclaimed sequence (9CI) (CA INDEX NAME)
SQL **58**
RN **631936-75-9** REGISTRY
SQL **58**

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMGSGI QRPTSTSSTS AAAFESRACS
=== ====
HITS AT: 18-24

REFERENCE 1: 140:26931

L13 ANSWER 4 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **625486-00-2** REGISTRY
CN 19: PN: WO03095619 SEQID: 22 unclaimed protein (9CI) (CA INDEX NAME)
SQL **62**
RN **625486-00-2** REGISTRY
SQL **62**

SEQ 1 MSGLNDIFEA QKIEWHEGAI SGGGGSGGGG SGGGGSAENL YFQGSSAHHH
=== ====
HITS AT: 38-44

REFERENCE 1: 139:393169

L13 ANSWER 5 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **625485-98-5** REGISTRY
CN 17: PN: WO03095619 SEQID: 20 unclaimed protein (9CI) (CA INDEX NAME)
NTE

type	------ location ------		description
uncommon	Aaa-48	-	-
uncommon	Aaa-49	-	-
uncommon	Aaa-50	-	-
uncommon	Aaa-51	-	-
uncommon	Aaa-52	-	-
uncommon	Aaa-53	-	-
uncommon	Aaa-54	-	-

SQL **54**
RN **625485-98-5** REGISTRY

SQL **54**

SEQ 1 MSGLNDIFEA QKIEWHEGAI SAENLYFQGS SAHHHHHHVL EVLFQGPXXX
=======

HITS AT: 23-29

REFERENCE 1: 139:393169

L13 ANSWER 6 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **625485-96-3** REGISTRY
CN 15: PN: WO03095619 SEQID: 18 unclaimed protein (9CI) (CA INDEX NAME)
SQL **67**
RN **625485-96-3** REGISTRY
SQL **67**

SEQ 1 MSGLNDIFEA QKIEWHEGAI SGGGGSGGGG SGGGGSAENL YFQGSSAHHH
=== ====

HITS AT: 38-44

REFERENCE 1: 139:393169

L13 ANSWER 7 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **625485-94-1** REGISTRY
CN 13: PN: WO03095619 SEQID: 16 unclaimed protein (9CI) (CA INDEX NAME)
SQL **52**
RN **625485-94-1** REGISTRY
SQL **52**

SEQ 1 MSGLNDIFEA QKIEWHEGAI SAENLYFQGS SAHHHHHHGS EDQVDPRLID
=======

HITS AT: 23-29

REFERENCE 1: 139:393169

L13 ANSWER 8 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **623534-89-4** REGISTRY
CN L-Serine, L-methionyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-tyrosyl-L-.alpha.-aspartyl-L-isoleucyl-L-prolyl-L-threonyl-L-alanyl-L-seryl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 12: PN: WO03095636 PAGE: 54 unclaimed sequence
SQL **24**
RN **623534-89-4** REGISTRY
SQL **24**

SEQ 1 MHHHHHHHHY DIPTASENLY FQGS
==== ===

HITS AT: 17-23

REFERENCE 1: 139:377249

L13 ANSWER 9 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **572898-80-7** REGISTRY
CN L-Serine, L-.alpha.-glutamyl-L-phenylalanyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-.alpha.-aspartyl-L-tyrosyl-L-.alpha.-aspartyl-L-isoleucyl-L-prolyl-L-threonyl-L-threonyl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 29: PN: CN1365983 PAGE: 5 unclaimed sequence
SQL **23**

RN **572898-80-7** REGISTRY
SQL **23**

SEQ 1 EFHHHHHHDY DIPTTENLYF QGS
=====
HITS AT: 16-22

REFERENCE 1: 139:144993

L13 ANSWER 10 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **504406-78-4** REGISTRY
CN L-Histidine, glycyl-L-seryl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2: PN: WO03027139 SEQID: 2 unclaimed sequence
SQL **14**
RN **504406-78-4** REGISTRY
SQL **14**

SEQ 1 GSENLYFQGH HHHH
=======
HITS AT: 3-9

REFERENCE 1: 138:282444

L13 ANSWER 11 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **503534-87-0** REGISTRY
CN L-Histidine, glycyl-L-seryl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 14: PN: WO03097789 SEQID: 8 unclaimed sequence
CN 20: PN: WO03089463 SEQID: 8 unclaimed sequence
CN 25: PN: WO03087352 SEQID: 2 unclaimed sequence
CN 2: PN: WO03025005 PAGE: 130 unclaimed sequence
CN 2: PN: WO03025006 SEQID: 2 unclaimed sequence
CN 2: PN: WO03025007 SEQID: 2 unclaimed sequence
CN 2: PN: WO03025008 SEQID: 2 unclaimed sequence
CN 2: PN: WO03045985 PAGE: 124 unclaimed sequence
CN 2: PN: WO03045986 SEQID: 2 unclaimed sequence
CN 2: PN: WO03051916 SEQID: 8 unclaimed sequence
CN 2: PN: WO03102190 SEQID: 2 unclaimed sequence
CN 8: PN: WO03055904 SEQID: 8 unclaimed sequence
CN 8: PN: WO2004011491 SEQID: 8 unclaimed sequence
CN 8: PN: WO2004013167 SEQID: 8 unclaimed sequence
SQL **15**
RN **503534-87-0** REGISTRY
SQL **15**

SEQ 1 GSENLYFQGH HHHHH
=======
HITS AT: 3-9

REFERENCE 1: 140:177316

REFERENCE 2: 140:159633

REFERENCE 3: 140:37977

REFERENCE 4: 140:2343

REFERENCE 5: 139:347484

REFERENCE 6: 139:334822

REFERENCE 7: 139:97272

REFERENCE 8: 139:65421

REFERENCE 9: 139:18838

REFERENCE 10: 139:18837

L13 ANSWER 12 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **500996-34-9** REGISTRY
CN Glycine, L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-.alpha.-aspartyl-L-tyrosyl-L-.alpha.-aspartyl-L-isoleucyl-L-prolyl-L-threonyl-L-threonyl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 18: PN: JP2003079379 SEQID: 18 unclaimed protein
SQL **20**
RN **500996-34-9** REGISTRY
SQL **20**

SEQ 1 HHHHHHDYDI PTTENLYFQG
=======
HITS AT: 14-20

REFERENCE 1: 138:216504

L13 ANSWER 13 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **474351-80-9** REGISTRY
CN 26: PN: WO02086507 FIGURE: 16 unclaimed sequence (9CI) (CA INDEX NAME)
SQL **85**
RN **474351-80-9** REGISTRY
SQL **85**

SEQ 1 NLLKICVFIF AFIMPVLIIT VCYGLMILRL KSVRMLSGSK EKDENLYFQG
=======
HITS AT: 44-50

REFERENCE 1: 137:346116

L13 ANSWER 14 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **474351-79-6** REGISTRY
CN 25: PN: WO02086507 FIGURE: 16 unclaimed sequence (9CI) (CA INDEX NAME)
SQL **77**
RN **474351-79-6** REGISTRY
SQL **77**

SEQ 1 LCKIVISIDY YNMFTSIFTL CTMSVDRYIA VCHPVKENLY FQGRNAKIIN
==== ===
HITS AT: 37-43

REFERENCE 1: 137:346116

L13 ANSWER 15 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **444875-83-6** REGISTRY
CN L-Valine, L-alanyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 11: PN: WO03006951 SEQID: 11 unclaimed sequence

CN 31: PN: WO02059144 SEQID: 31 unclaimed sequence
SQL **19**
RN **444875-83-6** REGISTRY
SQL **19**

SEQ 1 AYPYDVPDYA SENLYFQGV
=======
HITS AT: 12-18

REFERENCE 1: 138:119555

REFERENCE 2: 137:137275

L13 ANSWER 16 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **444875-82-5** REGISTRY
CN L-Alanine, L-alanyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 29: PN: WO02059144 SEQID: 29 unclaimed sequence
CN 9: PN: WO03006951 SEQID: 9 unclaimed sequence
SQL **19**
RN **444875-82-5** REGISTRY
SQL **19**

SEQ 1 AYPYDVPDYA SENLYFQGA
=======
HITS AT: 12-18

REFERENCE 1: 138:119555

REFERENCE 2: 137:137275

L13 ANSWER 17 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **444875-81-4** REGISTRY
CN Glycine, L-alanyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 28: PN: WO02059144 SEQID: 28 unclaimed sequence
CN 6: PN: WO03006951 SEQID: 8 unclaimed sequence
SQL **19**
RN **444875-81-4** REGISTRY
SQL **19**

SEQ 1 AYPYDVPDYA SENLYFQGG
=======
HITS AT: 12-18

REFERENCE 1: 138:119555

REFERENCE 2: 137:137275

L13 ANSWER 18 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **444875-80-3** REGISTRY
CN Glycine, L-alanyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 27: PN: WO02059144 SEQID: 27 unclaimed sequence

CN 7: PN: WO03006951 SEQID: 7 unclaimed sequence
SQL **18**
RN **444875-80-3** REGISTRY
SQL **18**

SEQ 1 AYPYDVPDYA SENLYFQG
=======
HITS AT: 12-18

REFERENCE 1: 138:119555

REFERENCE 2: 137:137275

L13 ANSWER 19 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **444875-79-0** REGISTRY
CN L-Arginine, L-alanyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl-L-valyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 16: PN: WO03006951 SEQID: 16 unclaimed sequence
CN 26: PN: WO02059144 SEQID: 26 unclaimed sequence
SQL **20**
RN **444875-79-0** REGISTRY
SQL **20**

SEQ 1 AYPYDVPDYA SENLYFQGVR
=======
HITS AT: 12-18

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:119555

REFERENCE 2: 137:137275

L13 ANSWER 20 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **444875-78-9** REGISTRY
CN L-Arginine, L-alanyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 14: PN: WO03006951 SEQID: 14 unclaimed sequence
CN 24: PN: WO02059144 SEQID: 24 unclaimed sequence
SQL **20**
RN **444875-78-9** REGISTRY
SQL **20**

SEQ 1 AYPYDVPDYA SENLYFQGAR
=======
HITS AT: 12-18

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:119555

REFERENCE 2: 137:137275

L13 ANSWER 21 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **444875-77-8** REGISTRY
CN L-Arginine, L-alanyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl-L-.alpha.-

glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 13: PN: WO03006951 SEQID: 13 unclaimed sequence
CN 23: PN: WO02059144 SEQID: 23 unclaimed sequence
SQL **20**
RN **444875-77-8** REGISTRY
SQL **20**

SEQ 1 AYPYDVPDYA SENLYFQGGR
=======
HITS AT: 12-18

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:119555

REFERENCE 2: 137:137275

L13 ANSWER 22 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **444875-76-7** REGISTRY
CN L-Arginine, L-alanyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 12: PN: WO03006951 SEQID: 12 unclaimed sequence
CN 22: PN: WO02059144 SEQID: 22 unclaimed sequence
SQL **19**
RN **444875-76-7** REGISTRY
SQL **19**

SEQ 1 AYPYDVPDYA SENLYFQGR
=======
HITS AT: 12-18

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:119555

REFERENCE 2: 137:137275

L13 ANSWER 23 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **444875-75-6** REGISTRY
CN L-Lysine, L-alanyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl-L-valyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 21: PN: WO02059144 SEQID: 21 unclaimed sequence
CN 5: PN: WO03006951 SEQID: 6 unclaimed sequence
SQL **20**
RN **444875-75-6** REGISTRY
SQL **20**

SEQ 1 AYPYDVPDYA SENLYFQGVK
=======
HITS AT: 12-18

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:119555

REFERENCE 2: 137:137275

L13 ANSWER 24 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **444875-74-5** REGISTRY
CN L-Lysine, L-alanyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 19: PN: WO02059144 SEQID: 19 unclaimed sequence
SQL **20**
RN **444875-74-5** REGISTRY
SQL **20**

SEQ 1 AYPYDVPDYA SENLYFQGAK
=======
HITS AT: 12-18

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:119555

REFERENCE 2: 137:137275

L13 ANSWER 25 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **444875-73-4** REGISTRY
CN L-Lysine, L-alanyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 18: PN: WO02059144 SEQID: 18 unclaimed sequence
CN 18: PN: WO03006951 SEQID: 18 unclaimed sequence
SQL **20**
RN **444875-73-4** REGISTRY
SQL **20**

SEQ 1 AYPYDVPDYA SENLYFQGGK
=======
HITS AT: 12-18

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:119555

REFERENCE 2: 137:137275

L13 ANSWER 26 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **444875-72-3** REGISTRY
CN L-Lysine, L-alanyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 17: PN: WO02059144 SEQID: 17 unclaimed sequence
CN 4: PN: WO03006951 SEQID: 5 unclaimed sequence
SQL **19**
RN **444875-72-3** REGISTRY
SQL **19**

SEQ 1 AYPYDVPDYA SENLYFQGK
=======
HITS AT: 12-18

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:119555

REFERENCE 2: 137:137275

L13 ANSWER 27 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **416230-90-5** REGISTRY
CN Glycine, L-methionyl-L-seryl-L-tyrosyl-L-tyrosyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-.alpha.-aspartyl-L-tyrosyl-L-.alpha.-aspartyl-L-isoleucyl-L-prolyl-L-threonyl-L-threonyl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl-L-serylglycyl-L-tyrosylglycyl-L-prolyl-L-lysyl-L-lysyl-L-lysyl-L-arginyl-L-lysyl-L-valylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 65: PN: US6376248 SEQID: 97 unclaimed protein
SQL **37**
RN **416230-90-5** REGISTRY
SQL **37**

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGSGYGPK KKRKVGG
=== ====
HITS AT: 18-24

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 136:336176

L13 ANSWER 28 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **366462-62-6** REGISTRY
CN 6XHis-tag fusion protein (Cloning vector pBS152v) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank AAG09293
CN GenBank AAG09293 (Translated from: GenBank AF177933)
SQL **57**
RN **366462-62-6** REGISTRY
SQL **57**

SEQ 1 MGHHHHHHDY DIPTTENLYF QGAHMGIQRP TSTSSLVAAA SRGSLEACGT
===== ==
HITS AT: 16-22

REFERENCE 1: 135:299437

L13 ANSWER 29 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **366024-87-5** REGISTRY
CN Galactosidase, .beta.- (Cloning vector pBS150v gene lacZa' alpha' fragment) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank AAG09290
CN GenBank AAG09290 (Translated from: GenBank AF177932)
SQL **97**
RN **366024-87-5** REGISTRY
SQL **97**

SEQ 1 MGHHHHHHDY DIPTTENLYF QGAHMGIQRP TSTRASLALA VVLQRRDWEN
===== ==
HITS AT: 16-22

REFERENCE 1: 135:299437

L13 ANSWER 30 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN

RN **298200-39-2** REGISTRY
CN 4: PN: WO0056763 SEQID: 4 unclaimed protein (9CI) (CA INDEX NAME)
SQL **58**
RN **298200-39-2** REGISTRY
SQL **58**

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMGIRN SKAYVDELTS RGRVDLNDDQ
=== ====
HITS AT: 18-24

REFERENCE 1: 133:271617

L13 ANSWER 31 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **292605-73-3** REGISTRY
CN L-Methionine, L-methionyl-L-seryl-L-tyrosyl-L-tyrosyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidylglycyl-L-isoleucyl-L-threonyl-L-seryl-L-leucyl-L-tyrosyl-L-lysyl-L-lysyl-L-alanylglycyl-L-phenylalanyl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl-L-threonyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 79: PN: WO0052027 PAGE: 131 claimed protein
SQL **30**
RN **292605-73-3** REGISTRY
SQL **30**

SEQ 1 MSYYHHHHHH GITSLYKKAG FENLYFQGTM
=======
HITS AT: 22-28

REFERENCE 1: 133:233572

L13 ANSWER 32 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **291276-58-9** REGISTRY
CN L-Isoleucine, L-leucyl-L-tyrosyl-L-lysyl-L-lysyl-L-alanylglycyl-L-phenylalanyl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl-L-threonyl-L-valyl-L-seryl-L-cysteinyl-L-isoleucyl-L-valyl-L-.alpha.-aspartyl-L-tryptophyl-L-isoleucyl-L-arginyl-L-tyrosyl-L-arginyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1: PN: WO0052141 FIGURE: 3 unclaimed sequence
SQL **27**
RN **291276-58-9** REGISTRY
SQL **27**

SEQ 1 LYKKAGFENL YFQGTVSCIV DWIRYRI
=== ====
HITS AT: 8-14

REFERENCE 1: 133:218507

L13 ANSWER 33 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **264266-32-2** REGISTRY
CN 43: PN: US6051429 SEQID: 97 unclaimed protein (9CI) (CA INDEX NAME)
SQL **37**
RN **264266-32-2** REGISTRY
SQL **37**

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGSGYGPK KKRKVGG
=== ====
HITS AT: 18-24

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 132:289590

L13 ANSWER 34 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **264236-19-3** REGISTRY
CN L-Serine, L-methionyl-L-seryl-L-tyrosyl-L-tyrosyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-.alpha.-aspartyl-L-tyrosyl-L-.alpha.-aspartyl-L-isoleucyl-L-prolyl-L-threonyl-L-threonyl-L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 43: PN: US6376248 SEQID: 96 unclaimed sequence
CN 57: PN: US6051429 SEQID: 96 unclaimed sequence
SQL **25**
RN **264236-19-3** REGISTRY
SQL **25**

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGS
=== ====
HITS AT: 18-24

REFERENCE 1: 136:336176

REFERENCE 2: 132:289590

L13 ANSWER 35 OF 35 REGISTRY COPYRIGHT 2004 ACS on STN
RN **158760-86-2** REGISTRY
CN Glycine, L-.alpha.-glutamyl-L-asparaginyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-glutaminyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glycine, N-[N2-[N-[N-[N-(N2-L-.alpha.-glutamyl-L-asparaginyl)-L-leucyl]-L-tyrosyl]-L-phenylalanyl]-L-glutaminyl]-
OTHER NAMES:
CN 12: PN: FR2830020 SEQID: 12 unclaimed sequence
CN 12: PN: WO03087152 SEQID: 14 unclaimed DNA
CN 1: PN: WO02059144 SEQID: 1 claimed protein
CN 1: PN: WO03006951 SEQID: 1 unclaimed sequence
CN 23: PN: CN1365983 PAGE: 4 unclaimed sequence
CN 27: PN: WO03095619 SEQID: 7 claimed protein
CN 2: PN: JP2003079379 SEQID: 2 claimed
CN 4: PN: WO0196539 SEQID: 5 unclaimed sequence
CN Fusion protein (synthetic cleavage sequences fragment)
SQL **7**
RN **158760-86-2** REGISTRY
SQL **7**

SEQ 1 ENLYFQG
=======
HITS AT: 1-7

REFERENCE 1: 139:393169

REFERENCE 2: 139:319015

REFERENCE 3: 139:144993

REFERENCE 4: 138:283688

REFERENCE 5: 138:216504

REFERENCE 6: 138:119555

REFERENCE 7: 137:137275

REFERENCE 8: 136:50271

REFERENCE 9: 133:218962

REFERENCE 10: 129:271524

=>
=>

```
=> d his l10-l14

     (FILE 'REGISTRY' ENTERED AT 10:00:13 ON 29 APR 2004)
L10          101 S L1 AND L9
L13           35 S L10 AND SQL<=100
L14           66 S L10 NOT L13

=> d .seq l14 1-66

L14  ANSWER 1 OF 66  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   670342-04-8  REGISTRY
CN   Kinase (phosphorylating), protein, nPKC (human) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   13: PN: WO2004022592 SEQID: 12 claimed protein
SQL  715
RN   670342-04-8  REGISTRY

SEQ      1 MSYYHHHHHH DYDIPTTENL YFQGITSLYK KAGSSGTMKF NGYLRVRIGE
                           === ====
HITS AT:   18-24

REFERENCE   1:  140:247082

L14  ANSWER 2 OF 66  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   670340-87-1  REGISTRY
CN   86: PN: US20040053384 SEQID: 86 unclaimed protein (9CI)  (CA INDEX NAME)
SQL  381
RN   670340-87-1  REGISTRY

SEQ      1 MGHHHHHHHD YDIPTTENLY FQGPVTQEFW DNLEKETEGL RQEMSKDLEE
                          ==== ===
HITS AT:   17-23

REFERENCE   1:  140:249011

L14  ANSWER 3 OF 66  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   670338-11-1  REGISTRY
CN   Scaffolding protein MSP1T3 (synthetic) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   80: PN: US20040053384 SEQID: 80 claimed protein
SQL  201
RN   670338-11-1  REGISTRY

SEQ      1 MGHHHHHHHD YDIPTTENLY FQGPVTQEFW DNLEKETEGL RQEMSKDLEE
                          ==== ===
HITS AT:   17-23

REFERENCE   1:  140:249011

L14  ANSWER 4 OF 66  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   670338-09-7  REGISTRY
CN   Scaffolding protein MSP1T2 (synthetic) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   78: PN: US20040053384 SEQID: 78 claimed protein
SQL  212
RN   670338-09-7  REGISTRY

SEQ      1 MGHHHHHHHD YDIPTTENLY FQGSTFSKLR EQLGPVTQEF WDNLEKETEG
                          ==== ===
HITS AT:   17-23

REFERENCE   1:  140:249011
```

L14 ANSWER 5 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **670338-07-5** REGISTRY
CN Scaffolding protein MSP1TEV (synthetic) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 76: PN: US20040053384 SEQID: 76 claimed protein
SQL 223
RN **670338-07-5** REGISTRY

SEQ 1 MGHHHHHHHD YDIPTTENLY FQGLKLLDNW DSVTSTFSKL REQLGPVTQE
==== ===
HITS AT: 17-23

REFERENCE 1: 140:249011

L14 ANSWER 6 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641653-94-3** REGISTRY
CN 46: PN: US20040001853 SEQID: 46 unclaimed protein (9CI) (CA INDEX NAME)
SQL 537
RN **641653-94-3** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDINA SRALANVYDL PDDFFPKIDD
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 7 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641653-92-1** REGISTRY
CN 44: PN: US20040001853 SEQID: 44 unclaimed protein (9CI) (CA INDEX NAME)
SQL 384
RN **641653-92-1** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF MGQHPAKSMD VRRIEGGEIL
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 8 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641653-90-9** REGISTRY
CN 41: PN: US20040001853 SEQID: 41 unclaimed protein (9CI) (CA INDEX NAME)
SQL 217
RN **641653-90-9** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF MGQHPAKSMD VRRIEGGEIL
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 9 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641653-87-4** REGISTRY
CN 29: PN: US20040001853 SEQID: 29 unclaimed protein (9CI) (CA INDEX NAME)
SQL 678
RN **641653-87-4** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPMG GWSSKPRKGM GTNLSVPNPL
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 10 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641653-61-4** REGISTRY
CN 74: PN: US20040001853 SEQID: 74 unclaimed protein (9CI) (CA INDEX NAME)
SQL 614
RN **641653-61-4** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF YQVRNSSGLY HVTNDCPNSS
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 11 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641653-58-9** REGISTRY
CN 64: PN: US20040001853 SEQID: 64 unclaimed protein (9CI) (CA INDEX NAME)
SQL 729
RN **641653-58-9** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF SGSWLRDIWD WICEVLSDFK
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 12 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641653-57-8** REGISTRY
CN 62: PN: US20040001853 SEQID: 62 unclaimed protein (9CI) (CA INDEX NAME)
SQL 505
RN **641653-57-8** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF SGSWLRDIWD WICEVLSDFK
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 13 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641653-55-6** REGISTRY
CN 56: PN: US20040001853 SEQID: 56 unclaimed protein (9CI) (CA INDEX NAME)
SQL 473
RN **641653-55-6** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF MSTNPKPQRK TKRNTNRRPQ
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 14 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641653-51-2** REGISTRY
CN 50: PN: US20040001853 SEQID: 50 unclaimed protein (9CI) (CA INDEX NAME)
SQL 289
RN **641653-51-2** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF KGLRRRAQLV RPQGGGSVDK
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 15 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-30-6** REGISTRY
CN Protein E1 (hepatitis C virus) fusion protein with protein E2 (hepatitis C

virus) fusion protein with with anti-(hepatitis B virus hepatitis B surface antigen S-protein) immunoglobulin G1 (mouse hybridoma 2C12 .gamma.1-chain CH1-hinge-CH2-CH3 region) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 11: PN: US20040001853 FIGURE: 58B claimed sequence
SQL 838
RN **641644-30-6** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF YQVRNSSGLY HVTNDCPNSS
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 16 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-28-2** REGISTRY
CN Protein E1 (hepatitis C virus) fusion protein with protein E2 (hepatitis C virus) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 9: PN: US20040001853 FIGURE: 57B claimed sequence
SQL 613
RN **641644-28-2** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF YQVRNSSGLY HVTNDCPNSS
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 17 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-26-0** REGISTRY
CN Protein E2 (hepatitis C virus) fusion protein with anti-(hepatitis B virus hepatitis B surface antigen S-protein) immunoglobulin G1 (mouse hybridoma 2C12 .gamma.1-chain CH1-hinge-CH2-CH3 region) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 7: PN: US20040001853 FIGURE: 56B claimed sequence
SQL 645
RN **641644-26-0** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF THVTGGNAGR TTAGLVGLLT
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 18 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-24-8** REGISTRY
CN Protein E2 (hepatitis C virus) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5: PN: US20040001853 FIGURE: 55B claimed sequence
SQL 421
RN **641644-24-8** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF THVTGGNAGR TTAGLVGLLT
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 19 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-22-6** REGISTRY
CN Protein E1 (hepatitis C virus) fusion protein with anti-(hepatitis B virus hepatitis B surface antigen S-protein) immunoglobulin G1 (mouse hybridoma

2C12 .gamma.1-chain CH1-hinge-CH2-CH3 region) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2: PN: US20040001853 FIGURE: 54B claimed sequence
SQL 475
RN **641644-22-6** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF YQVRNSSGLY HVTNDCPNSS
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 20 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-20-4** REGISTRY
CN Protein E1 (hepatitis C virus) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 113: PN: US20040001853 FIGURE: 53B claimed sequence
SQL 251
RN **641644-20-4** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF YQVRNSSGLY HVTNDCPNSS
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 21 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-18-0** REGISTRY
CN Protein NS5A (nonstructural, 5A) (hepatitis C virus) fusion protein with anti-(hepatitis B virus hepatitis B surface antigen S-protein) immunoglobulin G1 (mouse hybridoma 2C12 .gamma.1-chain CH1-hinge-CH2-CH3 region) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 111: PN: US20040001853 FIGURE: 52B claimed sequence
SQL 728
RN **641644-18-0** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF SGSWLRDIWD WICEVLSDFK
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 22 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-16-8** REGISTRY
CN Protein NS5A (nonstructural, 5A) (hepatitis C virus) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 109: PN: US20040001853 FIGURE: 51B claimed sequence
SQL 503
RN **641644-16-8** REGISTRY

SEQ 1 MSYYHHHHHD YDIPTTENLY FQGAMDPEFS GSWLRDIWDW ICEVLSDFKT
==== ===
HITS AT: 17-23

REFERENCE 1: 140:75949

L14 ANSWER 23 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-14-6** REGISTRY
CN 1-177-Hepatitis C core antigen (hepatitis C virus) fusion protein with anti-(hepatitis B virus hepatitis B surface antigen S-protein) immunoglobulin G1 (mouse hybridoma 2C12 .gamma.1-chain CH1-hinge-CH2-CH3

region) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 107: PN: US20040001853 FIGURE: 50B claimed sequence
SQL 459
RN **641644-14-6** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF MSTNPKPQRK TKRNTNRRPQ
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 24 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-12-4** REGISTRY
CN 1-177-Hepatitis C core antigen (hepatitis C virus) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 105: PN: US20040001853 FIGURE: 49B claimed sequence
SQL 235
RN **641644-12-4** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF MSTNPKPQRK TKRNTNRRPQ
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 25 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-10-2** REGISTRY
CN 1-191-Hepatitis C core antigen (hepatitis C virus) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 101: PN: US20040001853 FIGURE: 47B claimed sequence
SQL 249
RN **641644-10-2** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF MSTNPKPQRK TKRNTNRRPQ
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 26 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-08-8** REGISTRY
CN Hepatitis B core antigen (duck hepatitis B virus) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 99: PN: US20040001853 FIGURE: 24B claimed sequence
SQL 313
RN **641644-08-8** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDINA SRALANVYDL PDDFFPKIDD
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 27 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-06-6** REGISTRY
CN Hepatitis B core antigen (duck hepatitis B virus) fusion protein with anti-(hepatitis B virus hepatitis B surface antigen S-protein) immunoglobulin G1 (mouse hybridoma 2C12 .gamma.1-chain CH1-hinge-CH2-CH3 region) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 97: PN: US20040001853 FIGURE: 23B claimed sequence
SQL 537

RN **641644-06-6** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDINA SRALANVYDL PDDFFPKIDD
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 28 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-04-4** REGISTRY
CN Hepatitis B surface antigen pre-S protein (duck hepatitis B virus) fusion protein with hepatitis B surface antigen S-protein (duck hepatitis B virus) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 95: PN: US20040001853 FIGURE: 21B claimed sequence
SQL 386
RN **641644-04-4** REGISTRY

SEQ 1 MSYYHHHHHI IDYDIPTTEN LYFQGAMDPE FMGQHPAKSM DVRRIEGGEI
== =====
HITS AT: 19-25

REFERENCE 1: 140:75949

L14 ANSWER 29 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-02-2** REGISTRY
CN Hepatitis B surface antigen pre-S protein (duck hepatitis B virus) fusion protein with hepatitis B surface antigen S-protein (duck hepatitis B virus) fusion protein with anti-(hepatitis B virus hepatitis B surface antigen S-protein) immunoglobulin G1 (mouse hybridoma 2C12 .gamma.1-chain CH1-hinge-CH2-CH3 region) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 93: PN: US20040001853 FIGURE: 20B claimed sequence
SQL 608
RN **641644-02-2** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF MGQHPAKSMD VRRIEGGEIL
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 30 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641644-00-0** REGISTRY
CN Hepatitis B surface antigen pre-S protein (duck hepatitis B virus) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 91: PN: US20040001853 FIGURE: 18 claimed sequence
SQL 217
RN **641644-00-0** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF MGQHPAKSMD VRRIEGGKIL
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 31 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641643-98-3** REGISTRY
CN Hepatitis B surface antigen pre-S protein (duck hepatitis B virus) fusion protein with anti-(hepatitis B virus hepatitis B surface antigen S-protein) immunoglobulin G1 (mouse hybridoma 2C12 .gamma.1-chain CH1-hinge-CH2-CH3 region) (9CI) (CA INDEX NAME)

OTHER NAMES:
CN 89: PN: US20040001853 FIGURE: 17B claimed sequence
SQL 441
RN **641643-98-3** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF MGQHPAKSMD VRRIEGGEIL
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 32 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641643-96-1** REGISTRY
CN Hepatitis B core antigen (hepatitis B virus) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 87: PN: US20040001853 FIGURE: 15B claimed sequence
SQL 236
RN **641643-96-1** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDIDP YKEFGATVEL LSFLPSDFFP
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 33 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641643-94-9** REGISTRY
CN Hepatitis B core antigen (hepatitis B virus) fusion protein with anti-(hepatitis B virus hepatitis B surface antigen S-protein) immunoglobulin G1 (mouse hybridoma 2C12 .gamma.1-chain CH1-hinge-CH2-CH3 region) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 85: PN: US20040001853 FIGURE: 14B claimed sequence
SQL 460
RN **641643-94-9** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDIDP YKEFGATVEL LSFLPSDFFP
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 34 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641643-92-7** REGISTRY
CN Hepatitis B surface antigen pre-S1-protein (hepatitis B virus) fusion protein with hepatitis B surface antigen pre-S2-protein (hepatitis B virus) fusion protein with hepatitis B surface antigen S-protein (hepatitis B virus) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 83: PN: US20040001853 FIGURE: 12B claimed sequence
SQL 454
RN **641643-92-7** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPMG GWSSKPRKGM GTNLSVPNPL
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 35 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641643-90-5** REGISTRY
CN Hepatitis B surface antigen pre-S1-protein (hepatitis B virus) fusion protein with hepatitis B surface antigen pre-S2-protein (hepatitis B

virus) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 79: PN: US20040001853 FIGURE: 8B claimed sequence
SQL 228
RN **641643-90-5** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPMK KWSSKPRKGM GTNLSVPNPL
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 36 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **641643-88-1** REGISTRY
CN Hepatitis B surface antigen pre-S1-protein (hepatitis B virus) fusion protein with hepatitis B surface antigen pre-S2-protein (hepatitis B virus) fusion protein with anti-(hepatitis B virus hepatitis B surface antigen S-protein) immunoglobulin G1 (mouse hybridoma 2C12 .gamma.1-chain CH1-hinge-CH2-CH3 region) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 81: PN: US20040001853 FIGURE: 11B claimed sequence
SQL 452
RN **641643-88-1** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPMK KWSSKPRKGM GTNLSVPNPL
=== ====
HITS AT: 18-24

REFERENCE 1: 140:75949

L14 ANSWER 37 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **612560-03-9** REGISTRY
CN Terbofluor (synthetic oncomodulin-containing luminescent protein) fusion protein with enhanced green fluorescent protein (synthetic) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 8: PN: WO03087152 SEQID: 8 claimed protein
SQL 364
RN **612560-03-9** REGISTRY

SEQ 101 EFQEMVAESG GGGENLYFQG GGGGTMVSKG EELFTGVVPI LVELDGDVNG
=======
HITS AT: 114-120

REFERENCE 1: 139:319015

L14 ANSWER 38 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **602373-30-8** REGISTRY
CN 58: PN: US20030175925 FIGURE: 5D unclaimed sequence (9CI) (CA INDEX NAME)
SQL 295
RN **602373-30-8** REGISTRY

SEQ 1 MHHHHHHAEN LYFQGAMENS EKTEVVLLAC GSFNPITNMH LRLFELAKDY
== =====
HITS AT: 9-15

REFERENCE 1: 139:257286

L14 ANSWER 39 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **602373-28-4** REGISTRY
CN 54: PN: US20030175925 FIGURE: 5C unclaimed sequence (9CI) (CA INDEX NAME)
NTE
---

type	------ location ------		description
uncommon	Aaa-286	-	-
uncommon	Aaa-289	-	-

SQL 437
RN **602373-28-4** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMTSFD YLKTAIKQQG CTLQQVADAS
=== ====

HITS AT: 18-24

REFERENCE 1: 139:257286

L14 ANSWER 40 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **602373-26-2** REGISTRY
CN 50: PN: US20030175925 FIGURE: 5B unclaimed sequence (9CI) (CA INDEX NAME)
SQL 386
RN **602373-26-2** REGISTRY

SEQ 1 MHHHHHHAEN LYFQGAMAKT KEKKVGVIFG KFYPVHTGHI NMIYEAFSKV
== =====

HITS AT: 9-15

REFERENCE 1: 139:257286

L14 ANSWER 41 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **602373-24-0** REGISTRY
CN 46: PN: US20030175925 FIGURE: 5A unclaimed sequence (9CI) (CA INDEX NAME)
SQL 190
RN **602373-24-0** REGISTRY

SEQ 1 MHHHHHHAEN LYFQGAMAKT KEKKVGVIFG KFYPVHTGHI NMIYEAFSKV
== =====

HITS AT: 9-15

REFERENCE 1: 139:257286

L14 ANSWER 42 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **588806-56-8** REGISTRY
CN Peptide (synthetic 6-amino acid) fusion protein with botulin B (Clostridium botulinum light chain) fusion protein with peptide (synthetic tobacco etch virus cysteine proteinase cleavage site) fusion protein with botulin B (Clostridium botulinum heavy chain fragment) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 102: PN: US20030166238 SEQID: 102 claimed protein
SQL 864
RN **588806-56-8** REGISTRY

SEQ 401 EEGFNISDKD MEKEYRGQNK AINKQAYEEI SKEHLAVYKI QMCENLYFQG
=======

HITS AT: 444-450

REFERENCE 1: 139:207733

L14 ANSWER 43 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **558539-30-3** REGISTRY
CN 17: PN: WO03056032 SEQID: 29 unclaimed protein (9CI) (CA INDEX NAME)
SQL 126
RN **558539-30-3** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF EVNEKAPAQA RPTVFRWTGG

```
                                   === ====
HITS AT:    18-24

REFERENCE   1:  139:97274

L14  ANSWER 44 OF 66  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   537055-51-9  REGISTRY
CN   6: PN: WO03044166 FIGURE: 10 unclaimed protein (9CI)  (CA INDEX NAME)
SQL  183
RN   537055-51-9  REGISTRY

SEQ      1 MEKRRWKKNF IAVSAANRFK KISSSGALDY DIPTTASENL YFQGELKTAA
                                                   === ====
HITS AT:    38-44

REFERENCE   1:  139:18834

L14  ANSWER 45 OF 66  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   534241-68-4  REGISTRY
CN   Glycoprotein TAP (T-cell-activating protein) (synthetic plasmid pGEM3z-f
     fragment) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Glycoprotein TAP (T-cell-activating protein) (synthetic plasmid pGEM3z-f
     epitope tag)
SQL  208
RN   534241-68-4  REGISTRY

SEQ    101 PSQSANLLSE AKKLNESQAP KADNKFNKES STPTTASENL YFQGELKTAA
                                                   === ====
HITS AT:    138-144

REFERENCE   1:  139:1603

L14  ANSWER 46 OF 66  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   503640-32-2  REGISTRY
CN   Fusion protein (synthetic) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   13: PN: FR2830020 SEQID: 13 claimed protein
SQL  370
RN   503640-32-2  REGISTRY

SEQ    251 FIAVSAANRF KKISSSGALI DENLYFQGEL KHHHHHHLES CNLCHAYIHA
                                  =======
HITS AT:    272-278

REFERENCE   1:  138:283688

L14  ANSWER 47 OF 66  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   501070-34-4  REGISTRY
CN   28: PN: JP2003079379 SEQID: 28 unclaimed protein (9CI)  (CA INDEX NAME)
SQL  245
RN   501070-34-4  REGISTRY

SEQ      1 VVNSVLASAL ALTVAPMAFA AEEAATTTAP KMDADMEKTV DYDIPTTENL
                                                         ===
        51 YFQGFPTIPL SRLFDNAMLR AHRLHQLAFD TYQEFEEAYI PKEQKYSFLQ
           ====
HITS AT:    48-54

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  138:216504
```

L14 ANSWER 48 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **501070-33-3** REGISTRY
CN 27: PN: JP2003079379 SEQID: 27 unclaimed protein (9CI) (CA INDEX NAME)
SQL 251
RN **501070-33-3** REGISTRY

SEQ 51 PTTENLYFQG FPTIPLSRLF DNAMLRAHRL HQLAFDTYQE FEEAYIPKEQ
=======
HITS AT: 54-60

REFERENCE 1: 138:216504

L14 ANSWER 49 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **496833-40-0** REGISTRY
CN 1: PN: WO03010140 SEQID: 1 unclaimed protein (9CI) (CA INDEX NAME)
SQL 621
RN **496833-40-0** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF SMSYTWTGAL ITPCAAEESQ
=== ====
HITS AT: 18-24

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:153435

L14 ANSWER 50 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **496833-36-4** REGISTRY
CN 1: PN: WO03010141 SEQID: 1 unclaimed protein (9CI) (CA INDEX NAME)
SQL 621
RN **496833-36-4** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF SMSYTWTGAL ITPCAAEESQ
=== ====
HITS AT: 18-24

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:153436

L14 ANSWER 51 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **494821-37-3** REGISTRY
CN 1: PN: WO03007945 SEQID: 1 unclaimed protein (9CI) (CA INDEX NAME)
SQL 621
RN **494821-37-3** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF SMSYTWTGAL ITPCAAEESQ
=== ====
HITS AT: 18-24

REFERENCE 1: 138:153533

L14 ANSWER 52 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **474340-90-4** REGISTRY
CN 10: PN: WO02086507 SEQID: 16 unclaimed protein (9CI) (CA INDEX NAME)
SQL 399
RN **474340-90-4** REGISTRY

SEQ 251 TVCYGLMILR LKSVRMLSGS KEKDENLYFQ GRNLRRITRM VLVVVAVFIV
====== =
HITS AT: 275-281

REFERENCE 1: 137:346116

L14 ANSWER 53 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **474340-88-0** REGISTRY
CN 8: PN: WO02086507 SEQID: 14 unclaimed protein (9CI) (CA INDEX NAME)
SQL 392
RN **474340-88-0** REGISTRY

SEQ 151 YNMFTSIFTL CTMSVDRYIA VCHPVKENLY FQGRNAKIIN VCNWILSSAI
==== ===
HITS AT: 177-183

REFERENCE 1: 137:346116

L14 ANSWER 54 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **474340-84-6** REGISTRY
CN 4: PN: WO02086507 SEQID: 10 unclaimed protein (9CI) (CA INDEX NAME)
SQL 417
RN **474340-84-6** REGISTRY

SEQ 101 FGNFWCEFWT SIDVLCVTAS IETLCVIAVD RYFAITSPFK ENLYFQGLLT
=======
HITS AT: 141-147

REFERENCE 1: 137:346116

L14 ANSWER 55 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **474340-82-4** REGISTRY
CN 2: PN: WO02086507 SEQID: 8 unclaimed protein (9CI) (CA INDEX NAME)
SQL 413
RN **474340-82-4** REGISTRY

SEQ 251 DGRTGHGLEN LYFQGLKEHK ALKTLGIIMG TFTLCWLPFF IVNIVHVIQD
== =====
HITS AT: 259-265

REFERENCE 1: 137:346116

L14 ANSWER 56 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **466711-98-8** REGISTRY
CN 96: PN: WO02077036 FIGURE: 8 unclaimed sequence (9CI) (CA INDEX NAME)
SQL 197
RN **466711-98-8** REGISTRY

SEQ 1 MAAEFELYKM PENLYFQGEE EEEEEEEEEE EEEEEEEEEE EEEEEEEEEE
=======
HITS AT: 12-18

REFERENCE 1: 137:274074

L14 ANSWER 57 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **463371-73-5** REGISTRY
CN Oxygenase, inositol (synthetic human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 12: PN: WO02074926 SEQID: 12 claimed protein
SQL 310
RN **463371-73-5** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMEVTV GPDPSLVYRP DVDPEVAKDK
=== ====
HITS AT: 18-24

REFERENCE 1: 137:259337

L14 ANSWER 58 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **390883-37-1** REGISTRY
CN Protein NS5B (nonstructural, 5B) (heptatitis C virus) (9CI) (CA INDEX NAME)
SQL 620
RN **390883-37-1** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF SMSYTWTGAL ITPCAAEESQ
=== ====
HITS AT: 18-24

REFERENCE 1: 136:118447

L14 ANSWER 59 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **372211-82-0** REGISTRY
CN 7: PN: WO0183736 SEQID: 29 unclaimed protein (9CI) (CA INDEX NAME)
SQL 627
RN **372211-82-0** REGISTRY

SEQ 1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF EDVVCCSMSY TWTGALITPC
=== ====
HITS AT: 18-24

REFERENCE 1: 135:353893

L14 ANSWER 60 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **316202-99-0** REGISTRY
CN 45: PN: WO0100849 SEQID: 178 unclaimed protein (9CI) (CA INDEX NAME)
SQL 1099
RN **316202-99-0** REGISTRY

SEQ 1 MRGSHHHHHH DYDIPTTENL YFQGAMDPEF KGLRRPMAES SDKLYRVEYA
=== ====
HITS AT: 18-24

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 134:81787

L14 ANSWER 61 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **313289-58-6** REGISTRY
CN 59: PN: WO0077179 SEQID: 59 unclaimed protein (9CI) (CA INDEX NAME)
SQL 619
RN **313289-58-6** REGISTRY

SEQ 1 MRGSHHHHHH DYDIPTTENL YFQGAMDPEF KGLRRPMAAR RRRSTGGGRA
=== ====
HITS AT: 18-24

REFERENCE 1: 134:53138

L14 ANSWER 62 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **313289-46-2** REGISTRY
CN 47: PN: WO0077179 SEQID: 47 unclaimed protein (9CI) (CA INDEX NAME)
SQL 1063
RN **313289-46-2** REGISTRY

SEQ 1 MRGSHHHHHH DYDIPTTENL YFQGAMDPEF KGLRRPMAES SDKLYRVEYA
=== ====
HITS AT: 18-24

REFERENCE 1: 134:53138

L14 ANSWER 63 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **250232-55-4** REGISTRY
CN Cell wall protein (Bacillus N-terminal fragment) fusion protein with linker peptide fusion protein with somatotropin (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 66: PN: EP955370 SEQID: 66 claimed protein
SQL 245
RN **250232-55-4** REGISTRY

SEQ 1 VVNSVLASAL ALTVAPMAFA AEEAATTTAP KMDADMEKTV DYDIPTTENL
===
51 YFQGFPTIPL SRLFDNAMLR AHRLHQLAFD TYQEFEEAYI PKEQKYSFLQ
====
HITS AT: 48-54

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 131:347487

L14 ANSWER 64 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **221650-12-0** REGISTRY
CN Catalytic antibody ccMTLgL (synthetic) (9CI) (CA INDEX NAME)
SQL 482
RN **221650-12-0** REGISTRY

SEQ 301 AGGGSGGGSE NLYFQGGGGG SAEEVTIKAN LIFANGSTQT AEFKGTFEKA
= ======
HITS AT: 310-316

REFERENCE 1: 130:251215

L14 ANSWER 65 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **197923-73-2** REGISTRY
CN Bence-Jones protein fragment fusion protein with proteinase recognition domain (tobacco etch virus) fusion protein with protein L fragment (Peptostreptococcus magnus) fusion protein with 42-62-lysozyme (chicken) fusion protein with protein L fragment (Peptostreptococcus magnus) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Catalytic antibody TLHL (synthetic)
SQL 342
RN **197923-73-2** REGISTRY

SEQ 151 SGGGGSSGGG SGGGSENLYF QGGSAEEVTI KANLIFANGS TQTAEFKGTF
===== ==
HITS AT: 166-172

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 130:251215

REFERENCE 2: 127:328387

L14 ANSWER 66 OF 66 REGISTRY COPYRIGHT 2004 ACS on STN
RN **197923-71-0** REGISTRY
CN 1-31-Tumor necrosis factor (human) fusion protein with proteinase recognition domain (tobacco etch virus) fusion protein with protein L fragment (Peptostreptococcus magnus) fusion protein with 42-62-lysozyme (chicken) fusion protein with protein L fragment (Peptostreptococcus magnus) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Catalytic antibody CATAB-TEV (synthetic)

SQL 495
RN **197923-71-0** REGISTRY

SEQ 151 SGGGGSSGGG SGGGSENLYF QGGSAEEVTI KANLIFANGS TQTAEFKGTF
=====
351 GGSENLYFQG GGGGSGGGGD IVMTQSPDSL AVSLGERATI NCKSSQSVLY
=======

HITS AT: 166-172, 354-360

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 130:251215

REFERENCE 2: 127:328387